INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:575148 CAPLUS
DOCUMENT NUMBER: 134:36671
TITLE: Influence of the aliphatic spacer length on the 5-HT1A receptor activity of new arylpiperazines with an indazole system
AUTHOR(S): Paluchowska, Maria H.; Duszynska, Beata; Klodzinska, Aleksandra; Tatarczynska, Ewa
CORPORATE SOURCE: Department of Medicinal Chemistry, Polish Academy of Sciences, Krakow, PL 31-343, Pol.
SOURCE: Polish Journal of Pharmacology (2000), 52(3), 209-216
CODEN: PJPAE3; ISSN: 1230-6002
PUBLISHER: Polish Academy of Sciences, Institute of Pharmacology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Novel arylpiperazines, contg. a terminal 1- or 2-indazolyl fragment and a di- or tetramethylene aliph. spacer, were synthesized and their 5-HT1A and 5-HT2A receptor affinities were detd. All those compds. showed a potent affinity for 5-HT1A receptors (Ki = 5-16 nM) and were evaluated for an intrinsic activity at those receptors. To det. a 5-HT1A agonistic effect of the investigated compds., their ability to induce a lower lip retraction in rats and a behavioral syndrome (flat body posture and forepaw treading) in reserpinized rats were tested, whereas their 5-HT1A antagonistic activity was assessed via inhibition of those symptoms produced by 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT). The effect of spacer length on the 5-HT1A activity of the tested compds. was discussed in comparison with that of the 3-methylene analogs described earlier. Both dimethylene derivs. were characterized as weak postsynaptic 5-HT1A receptor antagonists. Compds. 1-indazolyl analog and 2-indazolyl analog, with a tetramethylene aliph. chain were classified as a postsynaptic 5-HT1A antagonist and a partial 5-HT1A agonist, resp. Furthermore, the latter showed a moderate anxiolytic-like effect (conflict drinking Vogel's test in rats) and a weak antidepressant-like activity (forced swimming Porsolt's test in rats).

IT 313053-44-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(arylpiperazines, new 5-HT1A receptor ligands)

RN 313053-44-0 CAPLUS
CN 1H-Indazole, 1-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:807683 CAPLUS
DOCUMENT NUMBER: 132:245821
TITLE: Structure-activity relationship studies of CNS agents. 40. Effect of the amide fragment on 5-HT1A receptor activity of some analogs of MP 3022
AUTHOR(S): Paluchowska, Maria H.; Charakchieva-Minol, Sijka; Tatarczynska, Ewa; Klodzinska, Aleksandra
CORPORATE SOURCE: Department of Medicinal Chemistry, Polish Academy of Sciences, Krakow, PL 31-343, Pol.
SOURCE: Polish Journal of Pharmacology (1999), 51(5), 415-421
CODEN: PJPAE3; ISSN: 1230-6002
PUBLISHER: Polish Academy of Sciences, Institute of Pharmacology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new set of analogs of MP 3022 (1) contg. the amide bond inserted into the intermediate chain linking the terminal heteroarom. and 1-(2-methoxyphenyl)piperazine moieties were prepd. and their 5-HT1A and 5-HT2A receptor affinities were detd. Only compds. with trimethylene chain between amide and arylpiperazine fragments showed satisfactory affinity for 5-HT1A receptor (Ki = 42-87 nM) and high 5-HT2A/5-HT1A selectivity. The new 5-HT1A receptor ligands were investigated in vivo to det. their 5-HT1A agonistic or antagonistic properties. Compds. with terminal indazole fragment or with Ph substituent behaved like weak 5-HT1A receptor antagonists. The structure-affinity relationship studies in this series of compds. revealed that the amide group along with the terminal arom. fragments contributed to interaction with 5-HT1A receptor sites, whereas in vivo results indicated that introduction of the amide group into presented arylpiperazine structures was not a profitable modification for their 5-HT1A functional activity.

IT **184535-35-1**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(5-HT1A receptor affinity of MP 3022 analogs)

RN 184535-35-1 CAPLUS
CN 1H-Indazole, 1-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



file copy

09/288,556



●2 HCl

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:807683 CAPLUS
DOCUMENT NUMBER: 132:245821
TITLE: Structure-activity relationship studies of CNS agents. 40. Effect of the amide fragment on 5-HT1A receptor activity of some analogs of MP 3022
AUTHOR(S): Paluchowska, Maria H.; Charakchieva-Minol, Sijka; Tatarczynska, Ewa; Klodzinska, Aleksandra
CORPORATE SOURCE: Department of Medicinal Chemistry, Polish Academy of Sciences, Krakow, PL 31-343, Pol.
SOURCE: Polish Journal of Pharmacology (1999), 51(5), 415-421
CODEN: PJPAE3; ISSN: 1230-6002
PUBLISHER: Polish Academy of Sciences, Institute of Pharmacology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new set of analogs of MP 3022 (1) contg. the amide bond inserted into the intermediate chain linking the terminal heteroarom. and 1-(2-methoxyphenyl)piperazine moieties were prepd. and their 5-HT1A and 5-HT2A receptor affinities were detd. Only compds. with trimethylene chain between amide and arylpiperazine fragments showed satisfactory affinity for 5-HT1A receptor (Ki = 42-87 nM) and high 5-HT2A/5-HT1A selectivity. The new 5-HT1A receptor ligands were investigated in vivo to det. their 5-HT1A agonistic or antagonistic properties. Compds. with terminal indazole fragment or with Ph substituent behaved like weak 5-HT1A receptor antagonists. The structure-affinity relationship studies in this series of compds. revealed that the amide group along with the terminal arom. fragments contributed to interaction with 5-HT1A receptor sites, whereas in vivo results indicated that introduction of the amide group into presented arylpiperazine structures was not a profitable modification for their 5-HT1A functional activity.

IT **184535-35-1**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(5-HT1A receptor affinity of MP 3022 analogs)

RN 184535-35-1 CAPLUS
CN 1H-Indazole, 1-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



file copy

09/288,556

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:193935 CAPLUS
DOCUMENT NUMBER: 130:237561
TITLE: Indole and indazole derivatives, process for their preparation and the pharmaceutical compositions containing them
INVENTOR(S): Lavielle, Gilbert; Muller, Olivier; Vayssettes-Courchay, Christine; Descombes, Jean-Jacques; Verbeuren, Tony
PATENT ASSIGNEE(S): Adir et Compagnie, Fr.
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 902027	A1	19990317	EP 1998-402154	19980901
EP 902027	B1	20010725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2767827	A1	19990305	FR 1997-10939	19970903
BR 9803318	A	20000208	BR 1998-3318	19980901
AT 203531	E	20010815	AT 1998-402154	19980901
ES 2162404	T3	20011216	ES 1998-402154	19980901
NO 9804033	A	19990304	NO 1998-4033	19980902
CN 1218052	A	19990602	CN 1998-124581	19980902
CN 1087741	B	20020717		
NZ 331683	A	20000128	NZ 1998-331683	19980902
US 6020336	A	20000201	US 1998-146009	19980902
CA 2246485	AA	19990303	CA 1998-2246485	19980903
ZA 9808072	A	19990309	ZA 1998-8072	19980903
AU 9883068	A1	19990318	AU 1998-83068	19980903
AU 736602	B2	20010802		
JP 11130773	A2	19990518	JP 1998-249314	19980903
US 6046205	A	20000404	US 1999-299314	19990426
HK 1019738	A1	20021101	HK 1999-104871	19991028

PRIORITY APPLN. INFO.: FR 1997-10939 A 19970903
US 1998-146009 A3 19980902

OTHER SOURCE(S): MARPAT 130:237561
GI



I

AB The title compds. I [n = 0, 1; A = bond, alkylene, alkenylene; X = N, CR2 where R2 = H, alkyl; R1 = H, alkyl; G1 = pyrrolidinyl, piperidyl, optionally substituted] were prepd. E.g., 1-{3-[4-(5-methoxypyrimidin-1-

yl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)indole dihydrochloride was prepd. Effect of I on contraction of saphenous vein of dogs or rabbits was detd.

IT **221249-30-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indole and indazole derivs. and their effect on saphenous vein contraction)

RN 221249-30-5 CAPLUS

CN 1H-Indazole, 1-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-6-(4H-1,2,4-triazol-4-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:148062 CAPLUS

DOCUMENT NUMBER: 130:276243

TITLE: Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1a serotonin and dopamine D1 receptors

AUTHOR(S): Andronati, S.; Sava, Vassil; Makan, S.; Kolodeev, G.

CORPORATE SOURCE: Bogatsky Physico-Chemical Institute, Nat. Acad. Sci. Ukraine, Odessa, 270086, Ukraine

SOURCE: Pharmazie (1999), 54(2), 99-101
CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Eight 3-arylindazole derivs. were synthesized and their affinity to 5-HT1A serotonin and D1 dopamine receptors was investigated by radioligand anal. Quant. structure-activity relationships were studied using the Free-Wilson model. An increase in affinity to dopamine D1 receptors within substituents Br>Cl>CH3 at the 5-position of the 3-arylindazole mol. was obsd. Addn. of a Cl2 atom to the ortho-position the of Ph ring let to even higher activity. Replacement of the H2 atom at the 1st position of the 3-arylindazole on the (phenylpiperazine)butyl substituent caused an increase of affinity and did not change the trends of affinity dependence on structure. An inverse dependence on the structure of the studied compds. was obsd. for the serotonin 5-HT1A receptors. Compds. contg. a Me group at the 5-position of mol. were more active than compds. contg. halogens. A Cl2 atom at the ortho-position of the Ph ring decreased affinity. Replacement of the H2 atom at the 1st position of the mol. on the (phenylpiperazine)butyl substituent led to an increase in affinity. Selectivity of the studied compds. varied within a wide range. Generally, the presence of the 3-arylindazole fragment in the new buspirone analogs increased their affinity to dopamine receptors and reduced their affinity to serotonin receptors. Compds. contg. a Br2 atom in the 3-arylindazole moiety may be promising ligands for D1 receptors.

IT **163434-05-7P 163434-06-8P 163434-07-9P 163434-08-0P**

yl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)indole dihydrochloride was prepd. Effect of I on contraction of saphenous vein of dogs or rabbits was detd.

IT **221249-30-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indole and indazole derivs. and their effect on saphenous vein contraction)

RN 221249-30-5 CAPLUS

CN 1H-Indazole, 1-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-6-(4H-1,2,4-triazol-4-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:148062 CAPLUS

DOCUMENT NUMBER: 130:276243

TITLE: Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1a serotonin and dopamine D1 receptors

AUTHOR(S): Andronati, S.; Sava, Vassil; Makan, S.; Kolodeev, G.

CORPORATE SOURCE: Bogatsky Physico-Chemical Institute, Nat. Acad. Sci. Ukraine, Odessa, 270086, Ukraine

SOURCE: Pharmazie (1999), 54(2), 99-101
CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Eight 3-arylindazole derivs. were synthesized and their affinity to 5-HT1A serotonin and D1 dopamine receptors was investigated by radioligand anal. Quant. structure-activity relationships were studied using the Free-Wilson model. An increase in affinity to dopamine D1 receptors within substituents Br>Cl>CH3 at the 5-position of the 3-arylindazole mol. was obsd. Addn. of a Cl2 atom to the ortho-position the of Ph ring let to even higher activity. Replacement of the H2 atom at the 1st position of the 3-arylindazole on the (phenylpiperazine)butyl substituent caused an increase of affinity and did not change the trends of affinity dependence on structure. An inverse dependence on the structure of the studied compds. was obsd. for the serotonin 5-HT1A receptors. Compds. contg. a Me group at the 5-position of mol. were more active than compds. contg. halogens. A Cl2 atom at the ortho-position of the Ph ring decreased affinity. Replacement of the H2 atom at the 1st position of the mol. on the (phenylpiperazine)butyl substituent led to an increase in affinity. Selectivity of the studied compds. varied within a wide range. Generally, the presence of the 3-arylindazole fragment in the new buspirone analogs increased their affinity to dopamine receptors and reduced their affinity to serotonin receptors. Compds. contg. a Br2 atom in the 3-arylindazole moiety may be promising ligands for D1 receptors.

IT **163434-05-7P 163434-06-8P 163434-07-9P**
163434-08-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of 3-arylindazole derivs. and their affinity to 5-HT1a serotonin and dopamine D1 receptors)

RN 163434-05-7 CAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163434-06-8 CAPLUS
CN 1H-Indazole, 5-bromo-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)





HCl

RN 163434-07-9 CAPLUS
CN 1H-Indazole, 5-bromo-3-(2-chlorophenyl)-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163434-08-0 CAPLUS
CN 1H-Indazole, 5-methyl-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1996:701302 CAPLUS
DOCUMENT NUMBER: 126:47180
TITLE: Structure-activity relationship studies of CNS agents. Part 31. Analogs of MP 3022 with a different number of nitrogen atoms in the heteroaromatic fragment. New 5-HT1A receptor ligands
AUTHOR(S): Paluchowska, Maria H.; Deren-Wesolek, Anna; Mokrosz, Jerzy L.; Charakchieva-Minol, Sijka; Chojnacka-Wojcik, Ewa

file copy

09/288,556



RN 400804-91-3 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400804-92-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:682542 CAPLUS
DOCUMENT NUMBER: 123:83356
TITLE: Preparation of 3-(1-piperazinyl)-1,2-benzisothiazole derivatives with antipsychotic effect
INVENTOR(S): Fukuda, Yoshimasa; Sasaki, Toshiro; Nakatani, Yuuko; Ichimaru, Yasuyuki; Imanishi, Taiichiro

09/288,556

PATENT ASSIGNEE(S): Meiji Seika K. K., Japan
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9418197	A1	19940818	WO 1994-JP159	19940203
W: CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 635506	A1	19950125	EP 1994-905841	19940203
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
CN 1103534	A	19950607	CN 1994-190042	19940203
CN 1050604	B	20000322		
US 5599815	A	19970204	US 1994-318857	19941220

PRIORITY APPLN. INFO.: JP 1993-17505 A 19930204
WO 1994-JP1 A 19940104
WO 1994-JP159 W 19940203

OTHER SOURCE(S): MARPAT 123:83356
GI



I



AB Compds. represented by general formula [I; n = 2-4; W = heterocyclyl, e.g., Q - Q2; m = 0-2; A = CH2, CH, N, NH; B = CH2, CH, N, NH, S; provided that both A and B .noteq. N or NH; X = CH, N, S, bond; Y = CH, N; R1 = H, halo, lower (halo)alkyl, (un)substituted Ph, OH, NO2, lower alkoxy, NH2, cyano; R2, R3 = H, halo, lower (halo)alkyl or alkoxy, NH2, cyano, provided that when X = bond, R2 is not present; or R2R3 = (CH2)p (wherein p = 3-5)] and pharmacol. acceptable salts thereof, reduced in the adverse effect against the extrapyramidal system and hence useful as an antipsychotic agent with few side effects, are prepd. Thus, 0.29 g 2-hydroxyquinoline was dissolved in DMF and treated with 80 mg NaH at 60.degree. for 30 min with stirring followed by cooling the reaction mixt. to room temp. and adding 2.16 g 1,4-dibromobutane and the resulting mixt. was stirred at 60.degree. for 4 h to give 64% 1-(4-bromobutyl)-2(1H)-quinolinone (II). II 0.56, 3-(1-piperazinyl)-1,2-benzisothiazole 0.44, and K2CO3 0.33 g were suspended in DMF and stirred at room temp. for 12 h to give 80% title

compd. I (n = 4, W = 2-oxo-1,2-dihydro-1-quinolinyl). II (n = 4, W = 9-carbazolyl) and II (n = 3, W = 2-oxo-1,2-dihydro-1-quinolinyl) showed ED50 of 1.15 and 0.92 mg/kg i.p., resp., for inhibiting methamphetamine-induced spontaneous movement of mice (vs. 0.16 and 1.05 mg/kg i.p. for haloperidol and chlorpromazine, resp.) and induced catalepsy in mice at ED50 of >100 and 83.3 mg/kg i.p. in mice (vs. 1.3 and 6.2 mg/kg i.p. for haloperidol and chlorpromazine, resp.).

IT **165109-38-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [N-(heterocyclylalkyl)piperazinyl]benzisothiazole derivs. as antipsychotics)

RN 165109-38-6 CAPLUS

CN 1,2-Benzisothiazole, 3-[4-[4-(3-chloro-1H-indazol-1-yl)butyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:34:53 ON 10 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     9 DEC 2003  HIGHEST RN 625365-36-8
DICTIONARY FILE UPDATES:    9 DEC 2003  HIGHEST RN 625365-36-8

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading 928122.str

L1      STRUCTURE UPLOADED

=>
Uploading 928122a.str

L2      STRUCTURE UPLOADED

=>
Uploading 928122b.str

L3      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 C,O,S,N

G2 C,S

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1 C,O,S,N

G2 C,S

G3 C,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 C,O,S,N

G2 C,S

G3 C,N

G4 O,S,N

G5 O,S

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 14:36:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    357 TO ITERATE

100.0% PROCESSED     357 ITERATIONS                          10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         6007 TO     8273
PROJECTED ANSWERS:              11 TO      389

L4            10 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 14:36:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   6868 TO ITERATE

100.0% PROCESSED    6868 ITERATIONS                         247 ANSWERS
SEARCH TIME: 00.00.01

L5           247 SEA SSS FUL L1

=> s l2
SAMPLE SEARCH INITIATED 14:37:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      2 TO ITERATE

100.0% PROCESSED       2 ITERATIONS                           0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:             2 TO      124
PROJECTED ANSWERS:                0 TO        0
```

09/288,556

```
L6             0 SEA SSS SAM L2

=> s l2 sss full
FULL SEARCH INITIATED 14:37:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      36 TO ITERATE

100.0% PROCESSED      36 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

L7             3 SEA SSS FUL L2

=> s l3
SAMPLE SEARCH INITIATED 14:37:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       2 TO ITERATE

100.0% PROCESSED       2 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            2 TO      124
PROJECTED ANSWERS:               1 TO       80

L8             1 SEA SSS SAM L3

=> s l3 sss full
FULL SEARCH INITIATED 14:37:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      24 TO ITERATE

100.0% PROCESSED      24 ITERATIONS                                9 ANSWERS
SEARCH TIME: 00.00.01

L9             9 SEA SSS FUL L3

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                              444.85     445.06

FILE 'CAPLUS' ENTERED AT 14:37:26 ON 10 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 10 Dec 2003  VOL 139 ISS 24
FILE LAST UPDATED: 9 Dec 2003  (20031209/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
```



●x HCl

=> s l7
L11 4 L7

=> d l11 1-4 ibib abs hitstr

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:300610 CAPLUS
DOCUMENT NUMBER: 138:304307
TITLE: Preparation of piperazinylpropylpyrazolopyridines for treatment of allergy
INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson, Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Tays, Kevin L.; Thumond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 47 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003073672	A1	20030417	US 2001-947041	20010905

PRIORITY APPLN. INFO.: US 2001-947041 20010905
OTHER SOURCE(S): MARPAT 138:304307
GI



I



I

AB Use of title compds. [I; R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, cyano, NO2, amino, acyl, etc.; R2 = H, halo, alkoxy, alkyl, alkenyl, haloalkyl, cyano, amino; R1R2, R5R6 = atoms to form a (substituted) (unsatd.) 5-7 membered (hetero)cycle; R3, R4 = H, alkyl; R5, R6 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, 4-7 membered carbocyclyl, heterocyclyl; Ar = (substituted) mono- or bicyclic aryl, heteroaryl; W = SO2, CO, bond, CHR20; R20 = H, alkyl, Ph, PhCH2, naphthyl, heterocyclyl; X = N, R12C; Y = N, R13C; Z = N, R14C; R12-R14 = H, halo, alkoxy, alkyl, alkenyl, cyano, NO2, amino, acyl, haloalkyl, heterocyclyl, heterocyclylalkyl, sulfonylamino, etc.; WR1 = atoms to form rings; G = (substituted) alkylene; n = 1,2], for treatment of allergy is claimed. Thus, 1-[3-(4-chlorophenyl)-1-(3-chloropropyl)-1,4,6,7-tetrahydropyrazolo[4.3-c]pyridin-5-yl]ethanone (prepn. given), 1-(2-fluorophenyl)piperazine, K2CO3, and Bu4NI were stirred in MeCN for 7 days to give 41% 1-[3-(4-chlorophenyl)-1-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone. The latter inhibited human cathepsin S with IC50 = 0.89 .mu.M.

IT **400802-64-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinylpropylpyrazolopyridines for treatment of allergy)

RN 400802-64-4 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(6-chloro-2-benzothiazolyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:282117 CAPLUS
DOCUMENT NUMBER: 138:304277
TITLE: Preparation of 3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as cathepsin S inhibitors for treating

09/288,556

allergies

INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson, Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Tays, Kevin L.; Thurmond, Robin L.; Wei, Jianmei

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 928,122.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003069240	A1	20030410	US 2002-75673	20020213
US 2002040020	A1	20020404	US 2001-928122	20010810

PRIORITY APPLN. INFO.: US 2001-928122 A2 20010810
US 2000-225138P P 20000814

OTHER SOURCE(S): MARPAT 138:304277

GI



I



II

AB Title compds. I [wherein Ar = (un)substituted mono- or bicyclic (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; W = SO2, CO, (un)substituted C, or a bond; or W and R1 taken together with the 6 membered ring to which they are attached form benzimidazolyl, benzothiazolyl, benz(is)oxazolyl, etc.; X, Y, and Z = independently N or (un)substituted C; R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, CN, NO2, acyl, or (un)substituted amino, carboxy, carbamoyl, or sulfamoyl; R2 = H, halo, alkoxy, (halo)alkyl, alkenyl, CN, or (un)substituted amino; or R1R2 = (un)substituted carbocyclic or heterocyclic ring; R3 and R4 = independently H or alkyl; R5 and R6 = independently H, alkyl, alkenyl, alkoxy, alkylthio, halo, carbocyclyl, or heterocyclyl; or R5R6 = (un)substituted carbocyclic or heterocyclic ring; n = 1-2; or pharmaceutically acceptable salts, amides, or esters thereof] were prepd.

as cathepsin S inhibitors for the treatment of an allergic condition, including an atopic allergic conditions. For example, N-acetyl-4-piperidone was condensed with morpholine in the presence of TsOH to give the enamine. Reaction with 4-ClC6H4COCl , followed by cycloaddn. with H2NNH2, gave 1-[3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone (42%). Alkylation with 1-bromo-3-chloropropane (83%) and addn. of 1-(2-fluorophenyl)piperazine afforded II (41%). The latter inhibited recombinant human cathepsin S with IC50 of 0.89 .mu.M.

IT **400802-64-4P**, 1-[1-[3-[4-(6-Chloro-benzothiazol-2-yl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiallergy agent; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-64-4 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(6-chloro-2-benzothiazolyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	2002:184899 CAPLUS
DOCUMENT NUMBER:	136:247576
TITLE:	Preparation of 3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as cathepsin S inhibitors for treating allergies
INVENTOR(S):	Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson, Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Tays, Kevin L.; Thurmond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S):	Ortho McNeil Pharmaceutical, Inc., USA
SOURCE:	PCT Int. Appl., 125 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002020012 A2 20020314 WO 2001-US27479 20010905
WO 2002020012 A3 20020613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002040020 A1 20020404 US 2001-928122 20010810
AU 2001088730 A5 20020322 AU 2001-88730 20010905
EP 1315491 A2 20030604 EP 2001-968486 20010905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 2000-230407P P 20000906
US 2001-928122 A 20010810
US 2000-225138P P 20000814
WO 2001-US27479 W 20010905
OTHER SOURCE(S): MARPAT 136:247576

GI



I



II

AB Title compds. I [wherein Ar = (un)substituted mono- or bicyclic (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; W = SO2, CO, (un)substituted C, or a bond; or W and R1 taken together with the 6 membered ring to which they are attached form benzimidazolyl, benzothiazolyl, benz(is)oxazolyl, etc.; X, Y, and Z = independently N or (un)substituted C; R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, CN, NO2, acyl, or (un)substituted amino, carboxy, carbamoyl, or sulfamoyl; R2 = H, halo, alkoxy, (halo)alkyl, alkenyl, CN, or (un)substituted amino; or R1R2 = (un)substituted carbocyclic or heterocyclic ring; R3 and R4 = independently H or alkyl; R5 and R6 = independently H, alkyl, alkenyl, alkoxy, alkylthio, halo, carbocyclyl, or heterocyclyl; or R5R6 = (un)substituted carbocyclic or heterocyclic ring; n = 1-2; or pharmaceutically acceptable salts, amides, or esters thereof] were prepd. as cathepsin S inhibitors for the treatment of an allergic condition,

including an atopic allergic conditions. For example, N-acetyl-4-piperidone was condensed with morpholine in the presence of TsOH to give the enamine. Reaction with 4-ClC6H4COCl , followed by cycloaddn. with H2NNH2, gave 1-[3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone (42%). Alkylation with 1-bromo-3-chloropropane (83%) and addn. of 1-(2-fluorophenyl)piperazine afforded II (41%). The latter inhibited recombinant human cathepsin S with IC50 of 0.89 .mu.M.

IT **400802-64-4P**, 1-[1-[3-[4-(6-Chloro-benzothiazol-2-yl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiallergy agent; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-64-4 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(6-chloro-2-benzothiazolyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:142707 CAPLUS
DOCUMENT NUMBER: 136:200181
TITLE: Substituted and/or fused pyrazoles, particularly piperazinylpropyl-substituted pyrazolopyridines, useful as cathepsin S inhibitors, and their pharmaceutical compositions and use as immunosuppressants
INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gustin, Darin J.; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Tays, Kevin L.; Wei, Jianmei
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002014314 A2 20020221 WO 2001-US25289 20010810
WO 2002014314 A3 20020606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2001081255 A5 20020225 AU 2001-81255 20010810
US 2002040020 A1 20020404 US 2001-928122 20010810
EP 1309591 A2 20030514 EP 2001-959731 20010810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 2000-225138P P 20000814
US 2001-928122 A 20010810
WO 2001-US25289 W 20010810
OTHER SOURCE(S): MARPAT 136:200181
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted pyrazoles I, methods of manufg. them, compns. contg. them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S, are described [R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, cyano, NO2, (un)substituted NH2, acyl, etc.; R2 = H, halo, alkoxy, alkyl, alkenyl, haloalkyl, cyano, or (un)substituted NH2; or R1R2 = atoms to form (un)substituted (un)satd. (non)arom. 5- to 7-membered carbo- or heterocyclic ring; R3, R4 = H, alkyl; R5, R6 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, or 4- to 7-membered carbo- or heterocyclyl; or R5R6 = atoms to form (un)substituted (un)satd. (non)arom. 5- to 7-membered carbo- or heterocyclic ring; n = 1 or 2; G = (un)substituted C3-6 alkanediyl or alkenediyl (substituents = OH, halo, oxo, aminoalkyl, etc.); X, Y, Z = N, (un)substituted CH; Ar = (un)substituted mono- or bicyclic (hetero)aryl; W = SO2, CO, (un)substituted CH2, bond; or WR1 = atoms to form a benzoxazol-2-yl, benzothiazol-2-yl, benzimidazol-2-yl, 1,2-benzisoxazol-3-yl, 1,2-benzisothiazol-3-yl, or 1,1-dioxo-1,2-benzothiazol-3-yl ring; including stereoisomers and pharmaceutically acceptable salts, esters, and amides]. Claimed usages include treatment of lupus, rheumatoid arthritis, and particularly asthma, and inhibition of tissue transplant rejection. Approx. 250 individual compds. I were prepd. and/or claimed, with detailed prepns. given for 24 compds. For instance, 4-(2-chloro-6-methanesulfonylaminophenyl)piperazine-1-carboxylic acid tert-Bu ester (prepd. in 4 steps) was deprotected with TFA and coupled with the corresponding epoxide (prepd. in several steps) to give title compd. II, a preferred compd. In an assay for inhibition of recombinant human cathepsin S in vitro, II had an IC50 of 0.06 .mu.M. Compd. III was another of three specifically preferred compds.

IT **400802-64-4P**, 1-[1-[3-[4-(6-Chlorobenzothiazol-2-yl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400805-11-0P**, 1-[1-[2-Hydroxy-3-[4-(6-nitrobenzothiazol-2-yl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400805-12-1P**, 1-[1-[2-Hydroxy-3-[4-(6-methoxybenzothiazol-2-yl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-

yl]ethanone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)

RN 400802-64-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(6-chloro-2-benzothiazolyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400805-11-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(6-nitro-2-benzothiazolyl)-1-piperazinyl]methyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400805-12-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(6-methoxy-2-benzothiazolyl)-1-piperazinyl]methyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



=> s l9
L12 5 L9

=> d l12 1-5 ibib abs hitstr

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:300610 CAPLUS
DOCUMENT NUMBER: 138:304307
TITLE: Preparation of piperazinylpropylpyrazolopyridines for treatment of allergy
INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson, Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Tays, Kevin L.; Thumond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 47 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003073672	A1	20030417	US 2001-947041	20010905

PRIORITY APPLN. INFO.: US 2001-947041 20010905
OTHER SOURCE(S): MARPAT 138:304307
GI



I

AB Use of title compds. [I; R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl,

cyano, NO2, amino, acyl, etc.; R2 = H, halo, alkoxy, alkyl, alkenyl, haloalkyl, cyano, amino; R1R2, R5R6 = atoms to form a (substituted) (unsatd.) 5-7 membered (hetero)cycle; R3, R4 = H, alkyl; R5, R6 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, 4-7 membered carbocyclyl, heterocyclyl; Ar = (substituted) mono- or bicyclic aryl, heteroaryl; W = SO2, CO, bond, CHR20; R20 = H, alkyl, Ph, PhCH2, naphthyl, heterocyclyl; X = N, R12C; Y = N, R13C; Z = N, R14C; R12-R14 = H, halo, alkoxy, alkyl, alkenyl, cyano, NO2, amino, acyl, haloalkyl, heterocyclyl, heterocyclylalkyl, sulfonylamino, etc.; WR1 = atoms to form rings; G = (substituted) alkylene; n = 1,2], for treatment of allergy is claimed. Thus, 1-[3-(4-chlorophenyl)-1-(3-chloropropyl)-1,4,6,7-tetrahydropyrazolo[4.3-c]pyridin-5-yl]ethanone (prepn. given), 1-(2-fluorophenyl)piperazine, K2CO3, and Bu4NI were stirred in MeCN for 7 days to give 41% 1-[3-(4-chlorophenyl)-1-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone. The latter inhibited human cathepsin S with IC50 = 0.89 .mu.M.

IT **400802-63-3P 400802-65-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinylpropylpyrazolopyridines for treatment of allergy)

RN 400802-63-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-65-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **400802-74-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of piperazinylpropylpyrazolopyridines for treatment of allergy)
RN 400802-74-6 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:282117 CAPLUS
DOCUMENT NUMBER: 138:304277
TITLE: Preparation of 3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as cathepsin S inhibitors for treating allergies
INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson, Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Tays, Kevin L.; Thurmond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 928,122.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003069240	A1	20030410	US 2002-75673	20020213
US 2002040020	A1	20020404	US 2001-928122	20010810

PRIORITY APPLN. INFO.: US 2001-928122 A2 20010810
US 2000-225138P P 20000814
OTHER SOURCE(S): MARPAT 138:304277
GI



I



II

AB Title compds. I [wherein Ar = (un)substituted mono- or bicyclic (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; W = SO2, CO, (un)substituted C, or a bond; or W and R1 taken together with the 6 membered ring to which they are attached form benzimidazolyl, benzothiazolyl, benz(is)oxazolyl, etc.; X, Y, and Z = independently N or (un)substituted C; R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, CN, NO2, acyl, or (un)substituted amino, carboxy, carbamoyl, or sulfamoyl; R2 = H, halo, alkoxy, (halo)alkyl, alkenyl, CN, or (un)substituted amino; or R1R2 = (un)substituted carbocyclic or heterocyclic ring; R3 and R4 = independently H or alkyl; R5 and R6 = independently H, alkyl, alkenyl, alkoxy, alkylthio, halo, carbocyclyl, or heterocyclyl; or R5R6 = (un)substituted carbocyclic or heterocyclic ring; n = 1-2; or pharmaceutically acceptable salts, amides, or esters thereof] were prepd. as cathepsin S inhibitors for the treatment of an allergic condition, including an atopic allergic conditions. For example, N-acetyl-4-piperidone was condensed with morpholine in the presence of TsOH to give the enamine. Reaction with 4-ClC6H4COCl , followed by cycloaddn. with H2NNH2, gave 1-[3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone (42%). Alkylation with 1-bromo-3-chloropropane (83%) and addn. of 1-(2-fluorophenyl)piperazine afforded II (41%). The latter inhibited recombinant human cathepsin S with IC50 of 0.89 .mu.M.

IT **400802-63-3P**, 1-[3-[4-(1,1-Dioxo-1H-benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400802-65-5P**, 1-[1-[3-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-2-hydroxy-propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-74-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiallergy agent; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-63-3 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-65-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-74-6 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:184899 CAPLUS
DOCUMENT NUMBER: 136:247576
TITLE: Preparation of 3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as cathepsin S inhibitors for treating

allergies

INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson, Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Tays, Kevin L.; Thurmond, Robin L.; Wei, Jianmei

PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020012	A2	20020314	WO 2001-US27479	20010905
WO 2002020012	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002040020	A1	20020404	US 2001-928122	20010810
AU 2001088730	A5	20020322	AU 2001-88730	20010905
EP 1315491	A2	20030604	EP 2001-968486	20010905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2000-230407P P 20000906
US 2001-928122 A 20010810
US 2000-225138P P 20000814
WO 2001-US27479 W 20010905

OTHER SOURCE(S): MARPAT 136:247576

GI



I



II

AB Title compds. I [wherein Ar = (un)substituted mono- or bicyclic (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; W = SO2, CO, (un)substituted C, or a bond; or W and R1 taken together with the 6 membered ring to which they are attached form benzimidazolyl, benzothiazolyl, benz(is)oxazolyl, etc.; X, Y, and Z = independently N or (un)substituted C; R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, CN, NO2, acyl, or (un)substituted amino, carboxy, carbamoyl, or sulfamoyl; R2 = H, halo, alkoxy, (halo)alkyl, alkenyl, CN, or (un)substituted amino; or R1R2 = (un)substituted carbocyclic or heterocyclic ring; R3 and R4 = independently H or alkyl; R5 and R6 = independently H, alkyl, alkenyl, alkoxy, alkylthio, halo, carbocyclyl, or heterocyclyl; or R5R6 = (un)substituted carbocyclic or heterocyclic ring; n = 1-2; or pharmaceutically acceptable salts, amides, or esters thereof] were prepd. as cathepsin S inhibitors for the treatment of an allergic condition, including an atopic allergic conditions. For example, N-acetyl-4-piperidone was condensed with morpholine in the presence of TsOH to give the enamine. Reaction with 4-ClC6H4COCl , followed by cycloaddn. with H2NNH2, gave 1-[3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone (42%). Alkylation with 1-bromo-3-chloropropane (83%) and addn. of 1-(2-fluorophenyl)piperazine afforded II (41%). The latter inhibited recombinant human cathepsin S with IC50 of 0.89 .mu.M.

IT **400802-63-3P**, 1-[3-[4-(1,1-Dioxo-1H-benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400802-65-5P**, 1-[1-[3-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-2-hydroxy-propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-74-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiallergy agent; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-63-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-65-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-74-6 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:142707 CAPLUS
DOCUMENT NUMBER: 136:200181
TITLE: Substituted and/or fused pyrazoles, particularly piperazinylpropyl-substituted pyrazolopyridines, useful as cathepsin S inhibitors, and their pharmaceutical compositions and use as immunosuppressants
INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gustin, Darin J.; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Tays, Kevin L.; Wei, Jianmei
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014314	A2	20020221	WO 2001-US25289	20010810
WO 2002014314	A3	20020606		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001081255	A5	20020225	AU 2001-81255 20010810
US 2002040020	A1	20020404	US 2001-928122 20010810
EP 1309591	A2	20030514	EP 2001-959731 20010810

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-225138P P 20000814
US 2001-928122 A 20010810
WO 2001-US25289 W 20010810

OTHER SOURCE(S): MARPAT 136:200181
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted pyrazoles I, methods of manufg. them, compns. contg. them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S, are described [R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, cyano, NO2, (un)substituted NH2, acyl, etc.; R2 = H, halo, alkoxy, alkyl, alkenyl, haloalkyl, cyano, or (un)substituted NH2; or R1R2 = atoms to form (un)substituted (un)satd. (non)arom. 5- to 7-membered carbo- or heterocyclic ring; R3, R4 = H, alkyl; R5, R6 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, or 4- to 7-membered carbo- or heterocyclyl; or R5R6 = atoms to form (un)substituted (un)satd. (non)arom. 5- to 7-membered carbo- or heterocyclic ring; n = 1 or 2; G = (un)substituted C3-6 alkanediyl or alkenediyl (substituents = OH, halo, oxo, aminoalkyl, etc.); X, Y, Z = N, (un)substituted CH; Ar = (un)substituted mono- or bicyclic (hetero)aryl; W = SO2, CO, (un)substituted CH2, bond; or WR1 = atoms to form a benzoxazol-2-yl, benzothiazol-2-yl, benzimidazol-2-yl, 1,2-benzisoxazol-3-yl, 1,2-benzisothiazol-3-yl, or 1,1-dioxo-1,2-benzothiazol-3-yl ring; including stereoisomers and pharmaceutically acceptable salts, esters, and amides]. Claimed usages include treatment of lupus, rheumatoid arthritis, and particularly asthma, and inhibition of tissue transplant rejection. Approx. 250 individual compds. I were prepd. and/or claimed, with detailed prepns. given for 24 compds. For instance, 4-(2-chloro-6-methanesulfonylaminophenyl)piperazine-1-carboxylic acid tert-Bu ester (prepd. in 4 steps) was deprotected with TFA and coupled with the corresponding epoxide (prepd. in several steps) to give title compd. II, a preferred compd. In an assay for inhibition of recombinant human cathepsin S in vitro, II had an IC50 of 0.06 .mu.M. Compd. III was another of three specifically preferred compds.

IT **400802-63-3P**, 1-[3-[4-[1,1-Dioxo-1.lambda.6-benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400802-65-5P**, 1-[1-[3-(4-Benzo[d]isoxazol-3-ylpiperazin-1-yl)-2-hydroxypropyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-74-6P**, 1-[3-(4-Benzo[d]isothiazol-3-ylpiperazin-1-yl)propyl]-3-(4-bromophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400804-88-8P**, 3-(4-Bromophenyl)-1-[3-[4-[1,1-dioxo-1.lambda.6-benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400804-89-9P**, 1-[1-[3-(4-Benzo[d]isothiazol-3-ylpiperazin-1-yl)propyl]-3-(4-bromophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-90-2P**,

1-[3-(4-Benzo[d]isothiazol-3-ylpiperazin-1-yl)propyl]-3-(4-bromophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400804-91-3P**, 1-[3-(4-Benzo[d]isothiazol-3-ylpiperazin-1-yl)propyl]-3-(4-bromophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400804-92-4P**, 1-[3-(4-Benzo[d]isothiazol-3-ylpiperazin-1-yl)propyl]-3-(4-bromophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)

RN 400802-63-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-65-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-74-6 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-88-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 3-(4-bromophenyl)-1-[3-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400804-89-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-90-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400804-91-3 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400804-92-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:682542 CAPLUS
DOCUMENT NUMBER: 123:83356
TITLE: Preparation of 3-(1-piperazinyl)-1,2-benzisothiazole derivatives with antipsychotic effect
INVENTOR(S): Fukuda, Yoshimasa; Sasaki, Toshiro; Nakatani, Yuuko; Ichimaru, Yasuyuki; Imanishi, Taiichiro

09/288,556

PATENT ASSIGNEE(S): Meiji Seika K. K., Japan
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9418197	A1	19940818	WO 1994-JP159	19940203
W: CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 635506	A1	19950125	EP 1994-905841	19940203
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
CN 1103534	A	19950607	CN 1994-190042	19940203
CN 1050604	B	20000322		
US 5599815	A	19970204	US 1994-318857	19941220

PRIORITY APPLN. INFO.: JP 1993-17505 A 19930204
WO 1994-JP1 A 19940104
WO 1994-JP159 W 19940203

OTHER SOURCE(S): MARPAT 123:83356
GI



I



AB Compds. represented by general formula [I; n = 2-4; W = heterocyclyl, e.g., Q - Q2; m = 0-2; A = CH2, CH, N, NH; B = CH2, CH, N, NH, S; provided that both A and B .noteq. N or NH; X = CH, N, S, bond; Y = CH, N; R1 = H, halo, lower (halo)alkyl, (un)substituted Ph, OH, NO2, lower alkoxy, NH2, cyano; R2, R3 = H, halo, lower (halo)alkyl or alkoxy, NH2, cyano, provided that when X = bond, R2 is not present; or R2R3 = (CH2)p (wherein p = 3-5)] and pharmacol. acceptable salts thereof, reduced in the adverse effect against the extrapyramidal system and hence useful as an antipsychotic agent with few side effects, are prepd. Thus, 0.29 g 2-hydroxyquinoline was dissolved in DMF and treated with 80 mg NaH at 60.degree. for 30 min with stirring followed by cooling the reaction mixt. to room temp. and adding 2.16 g 1,4-dibromobutane and the resulting mixt. was stirred at 60.degree. for 4 h to give 64% 1-(4-bromobutyl)-2(1H)-quinolinone (II). II 0.56, 3-(1-piperazinyl)-1,2-benzisothiazole 0.44, and K2CO3 0.33 g were suspended in DMF and stirred at room temp. for 12 h to give 80% title

compd. I (n = 4, W = 2-oxo-1,2-dihydro-1-quinolinyl). II (n = 4, W = 9-carbazolyl) and II (n = 3, W = 2-oxo-1,2-dihydro-1-quinolinyl) showed ED50 of 1.15 and 0.92 mg/kg i.p., resp., for inhibiting methamphetamine-induced spontaneous movement of mice (vs. 0.16 and 1.05 mg/kg i.p. for haloperidol and chlorpromazine, resp.) and induced catalepsy in mice at ED50 of >100 and 83.3 mg/kg i.p. in mice (vs. 1.3 and 6.2 mg/kg i.p. for haloperidol and chlorpromazine, resp.).

IT **165109-38-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [N-(heterocyclylalkyl)piperazinyl]benzisothiazole derivs. as antipsychotics)

RN 165109-38-6 CAPLUS

CN 1,2-Benzisothiazole, 3-[4-[4-(3-chloro-1H-indazol-1-yl)butyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



09/288,556

=> s l5
L10 14 L5

=> d l10 1-14 ibib abs hitstr

L10 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:300610 CAPLUS
DOCUMENT NUMBER: 138:304307
TITLE: Preparation of piperazinylpropylpyrazolopyridines for treatment of allergy
INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson, Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Tays, Kevin L.; Thumond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 47 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003073672	A1	20030417	US 2001-947041	20010905

PRIORITY APPLN. INFO.: US 2001-947041 20010905
OTHER SOURCE(S): MARPAT 138:304307
GI



I

AB Use of title compds. [I; R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, cyano, NO2, amino, acyl, etc.; R2 = H, halo, alkoxy, alkyl, alkenyl, haloalkyl, cyano, amino; R1R2, R5R6 = atoms to form a (substituted) (unsatd.) 5-7 membered (hetero)cycle; R3, R4 = H, alkyl; R5, R6 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, 4-7 membered carbocyclyl, heterocyclyl; Ar = (substituted) mono- or bicyclic aryl, heteroaryl; W = SO2, CO, bond, CHR20; R20 = H, alkyl, Ph, PhCH2, naphthyl, heterocyclyl; X = N, R12C; Y = N, R13C; Z = N, R14C; R12-R14 = H, halo, alkoxy, alkyl, alkenyl, cyano, NO2, amino, acyl, haloalkyl, heterocyclyl, heterocyclylalkyl, sulfonylamino, etc.; WR1 = atoms to form rings; G = (substituted) alkylene; n = 1,2], for treatment of allergy is claimed. Thus, 1-[3-(4-chlorophenyl)-1-(3-chloropropyl)-1,4,6,7-tetrahydropyrazolo[4.3-c]pyridin-5-yl]ethanone (prepn. given), 1-(2-fluorophenyl)piperazine, K2CO3, and Bu4NI were stirred in MeCN for 7 days to give 41% 1-[3-(4-chlorophenyl)-1-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone. The latter inhibited human cathepsin S with IC50 = 0.89 .mu.M.

IT **400802-47-3P 400802-70-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of piperazinylpropylpyrazolopyridines for treatment of allergy)

RN 400802-47-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-70-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-amino-6-chlorophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **400802-42-8P 400802-43-9P 400802-44-0P**
400802-45-1P 400802-46-2P 400802-49-5P
400802-50-8P 400802-51-9P 400802-52-0P
400802-53-1P 400802-54-2P 400802-55-3P
400802-56-4P 400802-57-5P 400802-58-6P
400802-59-7P 400802-60-0P 400802-61-1P
400802-62-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinylpropylpyrazolopyridines for treatment of allergy)

RN 400802-42-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-1-[3-[4-(2-fluorophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400802-43-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400802-44-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[2-methoxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-45-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-hydroxyphenyl)-1-piperazinyl]methyl]-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-46-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-49-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-N-[2-(1-piperazinyl)ethyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-50-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400802-51-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-52-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[2-[(aminocarbonyl)oxy]-3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-53-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-amino-4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400802-54-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-bromophenyl)-.alpha.-[[4-(5-chloro-2-methylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400802-55-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-fluoropropyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-56-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-acetic acid, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-.alpha.-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-57-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 4,5,6,7-tetrahydro-5-(methylsulfonyl)-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-58-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-[2-[(aminocarbonyl)amino]-6-chlorophenyl]-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-59-7 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-sulfonamide, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-60-0 CAPLUS
CN Methanesulfonamide, N-[3-chloro-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400802-61-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2,6-dinitrophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-62-2 CAPLUS
CN Benzoic acid, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-3-[(methylsulfonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



IT **400802-66-6 400802-67-7 400802-68-8**
400802-69-9 400802-71-3 400802-72-4
400802-73-5 400802-75-7 400802-76-8
400802-77-9 400802-78-0 400802-79-1
400802-80-4 400802-81-5 400802-82-6
400802-83-7 400802-84-8 400802-85-9
400802-86-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of piperazinylpropylpyrazolopyridines for treatment of allergy)

RN 400802-66-6 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-amino-6-chlorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-67-7 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-[6-chloro-2-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 400802-68-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-[2-chloro-6-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-69-9 CAPLUS
CN Benzoic acid, 3-amino-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-71-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-bromophenyl)-.alpha.-[[4-[2-chloro-6-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-72-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-73-5 CAPLUS
CN Carbamic acid, [3-chloro-2-[4-[3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-75-7 CAPLUS
CN Benzoic acid, 2-[4-[3-[5-acetyl-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-1-piperazinyl]-3-nitro-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-76-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-77-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-78-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-bromophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-79-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-80-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-81-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2,4-dimethylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400802-82-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(3,5-dichloro-4-pyridinyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-83-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-84-8 CAPLUS
CN Methanesulfonamide, N-[3-chloro-2-[4-[3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400802-85-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(3,4-dichlorophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-86-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



IT **400802-96-2P 400802-99-5P 400803-03-4P**
400803-04-5P 400803-06-7P 400803-07-8P
400803-08-9P 400803-09-0P 400803-10-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of piperazinylpropylpyrazolopyridines for treatment of allergy)
RN 400802-96-2 CAPLUS
CN Benzonitrile, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-3-(4-iodophenyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400802-99-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-nitrophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-03-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-04-5 CAPLUS
CN Benzonitrile, 2-[4-[3-[3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400803-06-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400803-07-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-08-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-amino-6-chlorophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-09-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-10-3 CAPLUS
CN Carbamic acid, [[1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-5H-pyrazolo[4,3-c]pyridin-5-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:282117 CAPLUS
DOCUMENT NUMBER: 138:304277
TITLE: Preparation of 3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as cathepsin S inhibitors for treating allergies
INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson,

09/288,556

Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Tays, Kevin L.; Thurmond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 928,122.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003069240	A1	20030410	US 2002-75673	20020213
US 2002040020	A1	20020404	US 2001-928122	20010810

PRIORITY APPLN. INFO.: US 2001-928122 A2 20010810
US 2000-225138P P 20000814
OTHER SOURCE(S): MARPAT 138:304277
GI



I



II

AB Title compds. I [wherein Ar = (un)substituted mono- or bicyclic (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; W = SO2, CO, (un)substituted C, or a bond; or W and R1 taken together with the 6 membered ring to which they are attached form benzimidazolyl, benzothiazolyl, benz(is)oxazolyl, etc.; X, Y, and Z = independently N or (un)substituted C; R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, CN, NO2, acyl, or (un)substituted amino, carboxy, carbamoyl, or sulfamoyl; R2 = H, halo, alkoxy, (halo)alkyl, alkenyl, CN, or (un)substituted amino; or R1R2 = (un)substituted carbocyclic or heterocyclic ring; R3 and R4 = independently H or alkyl; R5 and R6 = independently H, alkyl, alkenyl, alkoxy, alkylthio, halo, carbocyclyl, or heterocyclyl; or R5R6 = (un)substituted carbocyclic or heterocyclic ring; n = 1-2; or pharmaceutically acceptable salts, amides, or esters thereof] were prepd. as cathepsin S inhibitors for the treatment of an allergic condition, including an atopic allergic conditions. For example, N-acetyl-4-piperidone was condensed with morpholine in the presence of

TsOH to give the enamine. Reaction with 4-ClC6H4COCl , followed by cycloaddn. with H2NNH2, gave 1-[3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone (42%). Alkylation with 1-bromo-3-chloropropane (83%) and addn. of 1-(2-fluorophenyl)piperazine afforded II (41%). The latter inhibited recombinant human cathepsin S with IC50 of 0.89 .mu.M.

IT **400802-43-9P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-46-2P**, 1-[1-[2-Hydroxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-47-3P**, 2-(4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl)benzonitrile **400802-50-8P**, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400802-70-2P**, 3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenylamine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antiallergy agent; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-43-9 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400802-46-2 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-47-3 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-50-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400802-70-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-amino-6-chlorophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **400802-42-8P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-44-0P**, 1-[3-(4-Chlorophenyl)-1-[2-methoxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-45-1P**, 1-[1-[2-Hydroxy-3-[4-(2-hydroxyphenyl)piperazin-1-yl]propyl]-3-(4-iodophenyl)-1,4,6,7-

tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-49-5P**, 1-[1-[2-(2-Piperazin-1-yl-ethylamino)-3-(4-o-tolyl-piperazin-1-yl)propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-51-9P**, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxy-propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-52-0P**, Carbamic acid 1-[5-carbamoyl-3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-ylmethyl]-2-[4-(2-cyanophenyl)piperazin-1-yl]ethyl ester **400802-53-1P**, 1-[3-(3-Amino-4-chlorophenyl)-1-[2-hydroxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-54-2P**, (R)-1-(3-(4-Bromophenyl)-1-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone **400802-55-3P**, 2-(4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-fluoro-propyl]piperazin-1-yl)benzonitrile **400802-56-4P**, (3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxy-propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)oxoacetic acid methyl ester **400802-57-5P**, 5-Methanesulfonyl-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400802-58-6P**, 1-[3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c] pyridin-1-yl]propyl]piperazin-1-yl)phenyl]urea **400802-59-7P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-sulfonic acid amide **400802-60-0P**, N-[3-Chloro-2-(4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenyl]methanesulfonamide **400802-61-1P**, 1-[4-(2,6-Dinitrophenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400802-62-2P**, 2-(4-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)-3-[methanesulfonylamino]benzoic acid methyl ester **400802-66-6P**, 1-[4-(2-Amino-6-chlorophenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400802-67-7P**, 1-[3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c] pyridin-1-yl]propyl]piperazin-1-yl)phenyl]-3-methylurea **400802-68-8P**, 1-[3-Chloro-2-(4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenyl]-3-methylurea **400802-69-9P**, 3-Amino-2-(4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)benzoic acid methyl ester **400802-71-3P**, 1-[2-(4-[3-[3-(4-Bromophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl]piperazin-1-yl)-3-chlorophenyl]-3-methylurea **400802-72-4P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c] pyridine-5-carboxylic acid amide **400802-73-5P**, [3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenyl]carbamic acid methyl ester **400802-75-7P**, 2-(4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl)-3-nitrobenzoic acid methyl ester **400802-76-8P**, 1-[4-(2-Chloro-6-nitrophenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400802-77-9P**, 2-(4-[2-Hydroxy-3-[3-(4-iodophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)benzonitrile **400802-78-0P**,

3-(4-Bromophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-79-1P**, 2-(4-[3-[5-Acetyl-3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl]piperazin-1-yl)benzonitrile **400802-80-4P**, 2-(4-[3-[3-(4-Chloro-3-methylphenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl)benzonitrile **400802-81-5P**, 1-(3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2,4-dimethylphenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone **400802-82-6P**, 1-[3-[4-(3,5-Dichloro-pyridin-4-yl)piperazin-1-yl]propyl]-5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400802-83-7P**, 2-(4-[3-[5-Methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)benzonitrile **400802-84-8P**, N-[3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenyl]methanesulfonamide **400802-85-9P**, 3-(3,4-Dichlorophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-86-0P**, 3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **404028-96-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiallergy agent; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-42-8 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-1-[3-[4-(2-fluorophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400802-44-0 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[2-methoxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-45-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-hydroxyphenyl)-1-piperazinyl]methyl]-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-49-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-N-[2-(1-piperazinyl)ethyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-51-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-52-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[2-[(aminocarbonyl)oxy]-3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-53-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-amino-4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400802-54-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-bromophenyl)-.alpha.-[[4-(5-chloro-2-methylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400802-55-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-fluoropropyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-56-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-acetic acid, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-.alpha.-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-57-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 4,5,6,7-tetrahydro-5-(methylsulfonyl)-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-58-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-[2-[(aminocarbonyl)amino]-6-chlorophenyl]-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-59-7 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-sulfonamide, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-60-0 CAPLUS
CN Methanesulfonamide, N-[3-chloro-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400802-61-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2,6-dinitrophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-62-2 CAPLUS
CN Benzoic acid, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-3-[(methylsulfonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-66-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-amino-6-chlorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-67-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-[6-chloro-2-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-68-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-[2-chloro-6-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-69-9 CAPLUS
CN Benzoic acid, 3-amino-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-71-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-bromophenyl)-.alpha.-[[4-[2-chloro-6-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-72-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-73-5 CAPLUS
CN Carbamic acid, [3-chloro-2-[4-[3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-75-7 CAPLUS
CN Benzoic acid, 2-[4-[3-[5-acetyl-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-1-piperazinyl]-3-nitro-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-76-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-77-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-78-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-bromophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-79-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-80-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-81-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2,4-dimethylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400802-82-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(3,5-dichloro-4-pyridinyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-83-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-84-8 CAPLUS
CN Methanesulfonamide, N-[3-chloro-2-[4-[3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400802-85-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(3,4-dichlorophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-86-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 404028-96-2 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-sulfonic acid, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 404028-95-1
CMF C27 H32 Cl F3 N6 O5 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **400802-96-2P**, 2-(4-[2-Hydroxy-3-[3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)benzonitrile **400802-99-5P**, 1-[3-(4-Chloro-3-nitrophenyl)-1-[2-hydroxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-1,4.6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-03-4P**, 3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-04-5P**, 2-(4-[3-[3-(4-Chloro-3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl)benzonitrile **400803-06-7P**, 1-[3-[4-(2-Chloro-6-nitrophenyl)piperazin-1-yl]propyl]-5-methanesulfonyl-3-(4-

trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400803-07-8P**, 1-[3-[4-(2-Chloro-6-nitrophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-08-9P**, 1-[3-[4-(2-Amino-6-chlorophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-09-0P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-10-3P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-tert-butoxycarbonyl sulfonic acid amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-96-2 CAPLUS
CN Benzonitrile, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-3-(4-iodophenyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400802-99-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-nitrophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-03-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-04-5 CAPLUS
CN Benzonitrile, 2-[4-[3-[3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400803-06-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400803-07-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-08-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-amino-6-chlorophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-09-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-10-3 CAPLUS
CN Carbamic acid, [[1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-5H-pyrazolo[4,3-c]pyridin-5-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **404028-94-0P**, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)
RN 404028-94-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:940422 CAPLUS
DOCUMENT NUMBER: 138:304240
TITLE: Synthesis, molecular and crystal structure, and properties of 1-[4-(5-bromo-3-phenylindazol-1-yl)butyl]-4-phenylpiperazine 1-oxide hydrochloride
AUTHOR(S): Andronati, S. A.; Kolodeev, G. E.; Makan, S. Yu.; Simonov, Yu. A.; Chumakov, Yu. M.; Gdaniec, M.
CORPORATE SOURCE: Fiz.-Khim. Inst. im. A. V. Bogatskogo, NAN Ukr., Ukraine
SOURCE: Fiziologichno Aktivni Rechovini (2002), (1), 4-9
CODEN: FARICW
PUBLISHER: Natsional'na Farmatsevtichna Akademiya Ukraini
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 138:304240
GI



I

AB The title compd. (I) was prepd. by oxidn. of the piperazine deriv. with H2O2 in the presence of acetic acid in 1,4-dioxane. The mol. and crystal structure of I was studied by x-ray crystallog. and the CNDO/2 computation method. I is a complex obtained by proton transfer from HCl to the O of the N-oxide group. I showed no affinity for 5-HT1A receptors of the CNS.

IT **508169-76-4**
RL: PRP (Properties)
(CNDO/2 calcn. of structure of)

RN 508169-76-4 CAPLUS

CN 1H-Indazole, 5-bromo-1-[4-(1-oxido-4-phenyl-1-piperazinyl)butyl]-3-phenyl- (9CI) (CA INDEX NAME)



IT **508169-75-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-oxidn. by hydrogen peroxide)

RN 508169-75-3 CAPLUS

CN 1H-Indazole, 5-bromo-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]- (9CI) (CA INDEX NAME)



IT **508169-77-5P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and x-ray anal. of)

RN 508169-77-5 CAPLUS

CN 1H-Indazole, 5-bromo-1-[4-(1-oxido-4-phenyl-1-piperazinyl)butyl]-3-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:184899 CAPLUS
DOCUMENT NUMBER: 136:247576
TITLE: Preparation of 3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as cathepsin S inhibitors for treating allergies
INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson, Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Tays, Kevin L.; Thurmond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020012	A2	20020314	WO 2001-US27479	20010905
WO 2002020012	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002040020	A1	20020404	US 2001-928122	20010810
AU 2001088730	A5	20020322	AU 2001-88730	20010905
EP 1315491	A2	20030604	EP 2001-968486	20010905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2000-230407P P 20000906
US 2001-928122 A 20010810 ✓
US 2000-225138P P 20000814
WO 2001-US27479 W 20010905

OTHER SOURCE(S): MARPAT 136:247576
GI



I



II

AB Title compds. I [wherein Ar = (un)substituted mono- or bicyclic (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; W = SO2, CO, (un)substituted C, or a bond; or W and R1 taken together with the 6 membered ring to which they are attached form benzimidazolyl, benzothiazolyl, benz(is)oxazolyl, etc.; X, Y, and Z = independently N or (un)substituted C; R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, CN, NO2, acyl, or (un)substituted amino, carboxy, carbamoyl, or sulfamoyl; R2 = H, halo, alkoxy, (halo)alkyl, alkenyl, CN, or (un)substituted amino; or R1R2 = (un)substituted carbocyclic or heterocyclic ring; R3 and R4 = independently H or alkyl; R5 and R6 = independently H, alkyl, alkenyl, alkoxy, alkylthio, halo, carbocyclyl, or heterocyclyl; or R5R6 = (un)substituted carbocyclic or heterocyclic ring; n = 1-2; or pharmaceutically acceptable salts, amides, or esters thereof] were prepd. as cathepsin S inhibitors for the treatment of an allergic condition, including an atopic allergic conditions. For example, N-acetyl-4-piperidone was condensed with morpholine in the presence of TsOH to give the enamine. Reaction with 4-ClC6H4COCl , followed by cycloaddn. with H2NNH2, gave 1-[3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone (42%). Alkylation with 1-bromo-3-chloropropane (83%) and addn. of 1-(2-fluorophenyl)piperazine afforded II (41%). The latter inhibited recombinant human cathepsin S with IC50 of 0.89 .mu.M.

IT **400802-43-9P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-46-2P**, 1-[1-[2-Hydroxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-47-3P**, 2-(4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl)benzonitrile **400802-50-8P**, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400802-70-2P**, 3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenylamine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antiallergy agent; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-43-9 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400802-46-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-47-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-50-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400802-70-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-amino-6-chlorophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **400802-42-8P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-44-0P**, 1-[3-(4-Chlorophenyl)-1-[2-methoxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-45-1P**, 1-[1-[2-Hydroxy-3-[4-(2-hydroxyphenyl)piperazin-1-yl]propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-49-5P**, 1-[1-[2-(2-Piperazin-1-yl-ethylamino)-3-(4-o-tolyl-piperazin-1-yl)propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-51-9P**, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxy-propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-52-0P**, Carbamic acid 1-[5-carbamoyl-3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-ylmethyl]-2-[4-(2-cyanophenyl)piperazin-1-yl]ethyl ester **400802-53-1P**, 1-[3-(3-Amino-4-chlorophenyl)-1-[2-hydroxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-54-2P**, (R)-1-(3-(4-Bromophenyl)-1-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone **400802-55-3P**, 2-(4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-fluoro-propyl]piperazin-1-yl)benzonitrile **400802-56-4P**, (3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxy-propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)oxoacetic acid methyl ester **400802-57-5P**, 5-Methanesulfonyl-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400802-58-6P**, 1-[3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c] pyridin-1-yl]propyl]piperazin-1-yl)phenyl]urea **400802-59-7P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-

trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-sulfonic acid amide **400802-60-0P**, N-[3-Chloro-2-(4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenyl]methanesulfonamide **400802-61-1P**, 1-[4-(2,6-Dinitrophenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400802-62-2P**, 2-(4-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)-3-[methanesulfonylamino]benzoic acid methyl ester **400802-66-6P**, 1-[4-(2-Amino-6-chlorophenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400802-67-7P**, 1-[3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c] pyridin-1-yl]propyl]piperazin-1-yl)phenyl]-3-methylurea **400802-68-8P**, 1-[3-Chloro-2-(4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenyl]-3-methylurea **400802-69-9P**, 3-Amino-2-(4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)benzoic acid methyl ester **400802-71-3P**, 1-[2-(4-[3-[3-(4-Bromophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl]piperazin-1-yl)-3-chlorophenyl]-3-methylurea **400802-72-4P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c] pyridine-5-carboxylic acid amide **400802-73-5P**, [3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenyl]carbamic acid methyl ester **400802-75-7P**, 2-(4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl)-3-nitrobenzoic acid methyl ester **400802-76-8P**, 1-[4-(2-Chloro-6-nitrophenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400802-77-9P**, 2-(4-[2-Hydroxy-3-[3-(4-iodophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)benzonitrile **400802-78-0P**, 3-(4-Bromophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-79-1P**, 2-(4-[3-[5-Acetyl-3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl]piperazin-1-yl)benzonitrile **400802-80-4P**, 2-(4-[3-[3-(4-Chloro-3-methylphenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl)benzonitrile **400802-81-5P**, 1-(3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2,4-dimethylphenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone **400802-82-6P**, 1-[3-[4-(3,5-Dichloro-pyridin-4-yl)piperazin-1-yl]propyl]-5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400802-83-7P**, 2-(4-[3-[5-Methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)benzonitrile **400802-84-8P**, N-[3-Chloro-2-(4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)phenyl]methanesulfonamide **400802-85-9P**, 3-(3,4-Dichlorophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-86-0P**, 3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **404028-96-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiallergy agent; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-42-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-1-[3-[4-(2-fluorophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400802-44-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[2-methoxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-45-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-hydroxyphenyl)-1-piperazinyl]methyl]-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-49-5 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-N-[2-(1-piperazinyl)ethyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-51-9 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-52-0 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[2-[(aminocarbonyl)oxy]-3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-53-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-amino-4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400802-54-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-bromophenyl)-.alpha.-[[4-(5-chloro-2-methylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400802-55-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-fluoropropyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-56-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-acetic acid, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-.alpha.-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-57-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 4,5,6,7-tetrahydro-5-(methylsulfonyl)-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-58-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-[2-[(aminocarbonyl)amino]-6-chlorophenyl]-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-59-7 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-sulfonamide, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-60-0 CAPLUS
CN Methanesulfonamide, N-[3-chloro-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400802-61-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2,6-dinitrophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-62-2 CAPLUS
CN Benzoic acid, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-3-[(methylsulfonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-66-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-amino-6-chlorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME).



RN 400802-67-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-[6-chloro-2-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-68-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-[2-chloro-6-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-69-9 CAPLUS
CN Benzoic acid, 3-amino-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-71-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-bromophenyl)-.alpha.-[[4-[2-chloro-6-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-72-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-73-5 CAPLUS
CN Carbamic acid, [3-chloro-2-[4-[3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-75-7 CAPLUS
CN Benzoic acid, 2-[4-[3-[5-acetyl-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-1-piperazinyl]-3-nitro-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-76-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-77-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-78-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-bromophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-79-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-80-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-81-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2,4-dimethylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400802-82-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(3,5-dichloro-4-pyridinyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-83-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-84-8 CAPLUS
CN Methanesulfonamide, N-[3-chloro-2-[4-[3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400802-85-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(3,4-dichlorophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-86-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 404028-96-2 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-sulfonic acid, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 404028-95-1
CMF C27 H32 Cl F3 N6 O5 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **400802-96-2P**, 2-(4-[2-Hydroxy-3-[3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl)benzonitrile **400802-99-5P**, 1-[3-(4-Chloro-3-nitrophenyl)-1-[2-hydroxy-3-(4-o-tolyl-piperazin-1-yl)propyl]-1,4.6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-03-4P**, 3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-04-5P**, 2-(4-[3-[3-(4-Chloro-3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl)benzonitrile **400803-06-7P**, 1-[3-[4-(2-Chloro-6-nitrophenyl)piperazin-1-yl]propyl]-5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400803-07-8P**, 1-[3-[4-(2-Chloro-6-nitrophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-08-9P**, 1-[3-[4-(2-Amino-6-chlorophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-09-0P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-10-3P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-tert-butoxycarbonyl sulfonic acid amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)

RN 400802-96-2 CAPLUS

CN Benzonitrile, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-3-(4-iodophenyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400802-99-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-nitrophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-03-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-04-5 CAPLUS
CN Benzonitrile, 2-[4-[3-[3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400803-06-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400803-07-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-08-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-amino-6-chlorophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-09-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-10-3 CAPLUS
CN Carbamic acid, [[1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-5H-pyrazolo[4,3-c]pyridin-5-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **404028-94-0P**, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyrazolopyridines antiallergy agents starting from piperidones, benzoyl chlorides and hydrazine)
RN 404028-94-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI)

(CA INDEX NAME)



L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:142707 CAPLUS
DOCUMENT NUMBER: 136:200181
TITLE: Substituted and/or fused pyrazoles, particularly piperazinylpropyl-substituted pyrazolopyridines, useful as cathepsin S inhibitors, and their pharmaceutical compositions and use as immunosuppressants
INVENTOR(S): Breitenbucher, J. Guy; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gustin, Darin J.; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Tays, Kevin L.; Wei, Jianmei
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014314	A2	20020221	WO 2001-US25289	20010810
WO 2002014314	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001081255	A5	20020225	AU 2001-81255	20010810
US 2002040020	A1	20020404	US 2001-928122	20010810
EP 1309591	A2	20030514	EP 2001-959731	20010810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-225138P P 20000814
US 2001-928122 A 20010810
WO 2001-US25289 W 20010810
OTHER SOURCE(S): MARPAT 136:200181
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted pyrazoles I, methods of manufg. them, compns. contg. them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S, are described [R1 = H, N3, halo, alkoxy, OH, alkyl, alkenyl, cyano, NO2, (un)substituted NH2, acyl, etc.; R2 = H, halo, alkoxy, alkyl, alkenyl, haloalkyl, cyano, or (un)substituted NH2; or R1R2 = atoms to form (un)substituted (un)satd. (non)arom. 5- to 7-membered carbo- or heterocyclic ring; R3, R4 = H, alkyl; R5, R6 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, or 4- to 7-membered carbo- or heterocyclyl; or R5R6 = atoms to form (un)substituted (un)satd. (non)arom. 5- to 7-membered carbo- or heterocyclic ring; n = 1 or 2; G = (un)substituted C3-6 alkanediyl or alkenediyl (substituents = OH, halo, oxo, aminoalkyl, etc.); X, Y, Z = N, (un)substituted CH; Ar = (un)substituted mono- or bicyclic (hetero)aryl; W = SO2, CO, (un)substituted CH2, bond; or WR1 = atoms to form a benzoxazol-2-yl, benzothiazol-2-yl, benzimidazol-2-yl, 1,2-benzisoxazol-3-yl, 1,2-benzisothiazol-3-yl, or 1,1-dioxo-1,2-benzothiazol-3-yl ring; including stereoisomers and pharmaceutically acceptable salts, esters, and amides]. Claimed usages include treatment of lupus, rheumatoid arthritis, and particularly asthma, and inhibition of tissue transplant rejection. Approx. 250 individual compds. I were prepd. and/or claimed, with detailed prepns. given for 24 compds. For instance, 4-(2-chloro-6-methanesulfonylaminophenyl)piperazine-1-carboxylic acid tert-Bu ester (prepd. in 4 steps) was deprotected with TFA and coupled with the corresponding epoxide (prepd. in several steps) to give title compd. II, a preferred compd. In an assay for inhibition of recombinant human cathepsin S in vitro, II had an IC50 of 0.06 .mu.M. Compd. III was another of three specifically preferred compds.

IT **400802-43-9P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-46-2P**, 1-[1-[2-Hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-47-3P**, 2-[4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400802-50-8P**, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400802-70-2P**, 3-Chloro-2-[4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]phenylamine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of piperazinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)

RN 400802-43-9 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400802-46-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-47-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-50-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400802-70-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-amino-6-chlorophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **400802-42-8P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-44-0P**, 1-[3-(4-Chlorophenyl)-1-[2-methoxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-45-1P**, 1-[1-[2-Hydroxy-3-[4-(2-hydroxyphenyl)piperazin-1-yl]propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-49-5P**, 1-[1-[2-[[2-(Piperazin-1-yl)ethyl]amino]-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-51-9P**, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-52-0P**, Carbamic acid 1-[[5-(carbamoyl)-3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]methyl]-2-[4-(2-cyanophenyl)piperazin-1-yl]ethyl ester **400802-53-1P**, 1-[3-(3-Amino-4-chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-54-2P**, (R)-1-[3-(4-Bromophenyl)-1-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-55-3P**, 2-[4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-fluoropropyl]piperazin-1-yl]benzonitrile **400802-56-4P**, [3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]oxoacetic acid methyl ester **400802-57-5P**, 5-Methanesulfonyl-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400802-58-6P**, 1-[3-Chloro-2-[4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]phenyl]urea **400802-59-7P**,

1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-sulfonic acid amide **400802-60-0P**, N-[3-Chloro-2-[4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]phenyl]methanesulfonamide **400802-61-1P**, 1-[4-(2,6-Dinitrophenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400802-62-2P**, 2-[4-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]-3-methanesulfonylaminobenzoic acid methyl ester **400802-66-6P**, 1-[4-(2-Amino-6-chlorophenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400802-67-7P**, 1-[3-Chloro-2-[4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]phenyl]-3-methylurea **400802-68-8P**, 1-[3-Chloro-2-[4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]phenyl]-3-methylurea **400802-69-9P**, 3-Amino-2-[4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]benzoic acid methyl ester **400802-71-3P**, 1-[2-[4-[3-[3-(4-Bromophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]-3-chlorophenyl]-3-methylurea **400802-72-4P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-73-5P**, [3-Chloro-2-[4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]phenyl]carbamic acid methyl ester **400802-75-7P**, 2-[4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]-3-nitrobenzoic acid methyl ester **400802-76-8P**, 1-[4-(2-Chloro-6-nitrophenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400802-77-9P**, 2-[4-[2-Hydroxy-3-[3-(4-iodophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]benzonitrile **400802-78-0P**, 3-(4-Bromophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-79-1P**, 2-[4-[3-[5-Acetyl-3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400802-80-4P**, 2-[4-[3-[3-(4-Chloro-3-methylphenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400802-81-5P**, 1-[3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2,4-dimethylphenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400802-82-6P**, 1-[3-[4-(3,5-Dichloropyridin-4-yl)piperazin-1-yl]propyl]-5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400802-83-7P**, 2-[4-[3-[5-Methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]benzonitrile **400802-84-8P**, N-[3-Chloro-2-[4-[3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]phenyl]methanesulfonamide **400802-85-9P**, 3-(3,4-Dichlorophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-86-0P**, 3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400802-87-1P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piper

azin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-sulfonic acid amide trifluoroacetate **400803-17-0P**, 1-[3-(4-Chlorophenyl)-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-18-1P**, 1-[1-[3-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-hydroxypropyl]-3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-19-2P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-20-5P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2-chlorophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-21-6P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(3-chlorophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-22-7P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(4-chlorophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-23-8P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2-fluorophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-24-9P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(4-fluorophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-25-0P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-26-1P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(4-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-27-2P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-28-3P**, 1-[1-[3-(4-Benzhydrylpiperazin-1-yl)-2-hydroxypropyl]-3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-29-4P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-31-8P**, 1-[1-[3-(4-Benzylpiperazin-1-yl)-2-hydroxypropyl]-3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-33-0P**, 1-[1-[2-Hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-34-1P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(2-trifluoromethylphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-35-2P**, 1-[3-(4-Fluorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-37-4P**, 1-[1-[2-Hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-p-tolyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-38-5P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(3,4-dichlorophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-39-6P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(pyridin-2-yl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-40-9P**, 1-[3-Biphenyl-4-yl-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-41-0P**, 1-[1-[2-Hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-phenyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-42-1P**, 1-[1-[2-Hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-(4-methoxyphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-43-2P**, 1-[1-[2-Hydroxy-3-[4-(pyridin-4-yl)piperazin-1-yl]propyl]-3-(4-methoxyphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-45-4P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-46-5P**, 1-[1-[2-Hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-naphthalen-

2-yl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-47-6P**, 1-[3-(4-tert-Butylphenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-48-7P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]butan-1-one **400803-49-8P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethylpropan-1-one **400803-50-1P**, [3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl](4-methoxyphenyl)methanone **400803-51-2P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400803-52-3P**, 1-[3-(4-Chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-2-ol **400803-53-4P**, 1-[3-(3,4-Dichlorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-54-5P**, 1-[1-[2-Hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-55-6P**, 1-[1-[2-Hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-(4-nitrophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-56-7P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2,4-difluorophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-57-8P**, 2-[4-[3-[5-Acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400803-59-0P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2,3-dimethylphenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-60-3P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2,4-dimethylphenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-61-4P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-62-5P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-(3-methyl-4-p-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-63-6P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-(3-methyl-4-m-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-64-7P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(4-trifluoromethylpyridin-2-yl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-65-8P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(3-chloro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-66-9P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(3,5-dichloropyridin-4-yl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-67-0P**, 1-[3-(4-Chlorophenyl)-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]but-2-enyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-68-1P**, 4-[5-Acetyl-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitrile **400803-71-6P**, 1-[3-(2,4-Bistrifluoromethylphenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-72-7P**, 1-[3-(2,4-Dichlorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-73-8P**, 2-[4-[3-[3-(4-Chlorophenyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400803-74-9P**, 2-[4-[3-[3-(4-Chlorophenyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-1-yl]-2-hydroxypropyl]piperazin-1-yl]phenol **400803-75-0P**, 1-[3-(4-Bromophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-

yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-76-1P**, 1-[3-(4-Chlorophenyl)-1-[2-[(2-methylallyl)oxy]-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-77-2P**, 1-[1-[2-Benzyloxy-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-78-3P**, Acetic acid 1-[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-ylmethyl]-2-(4-o-tolylpiperazin-1-yl)ethyl ester **400803-79-4P**, Morpholine-4-carboxylic acid 1-[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-ylmethyl]-2-(4-o-tolylpiperazin-1-yl)ethyl ester **400803-80-7P**, Benzoic acid 1-[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-ylmethyl]-2-(4-o-tolylpiperazin-1-yl)ethyl ester **400803-81-8P**, Benzoylcarbamic acid 1-[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-ylmethyl]-2-(4-o-tolylpiperazin-1-yl)ethyl ester **400803-83-0P**, 1-[3-(3-Chlorophenyl)-1-[2-hydroxy-3-[4-(2-hydroxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-84-1P**, 2-[4-[3-[5-Acetyl-3-(3-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400803-85-2P**, tert-Butylcarbamic acid 1-[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-ylmethyl]-2-(4-o-tolylpiperazin-1-yl)ethyl ester **400803-86-3P**, Carbonic acid 1-[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-ylmethyl]-2-(4-o-tolylpiperazin-1-yl)ethyl ester methyl ester **400803-87-4P**, 1-[3-(4-Chlorophenyl)-1-[4-[4-(2-hydroxyphenyl)piperazin-1-yl]but-2-enyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-88-5P**, 2-[4-[4-[5-Acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]but-2-enyl]piperazin-1-yl]benzonitrile **400803-89-6P**, 1-[3-(4-Chlorophenyl)-1-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-90-9P**, 1-[3-(4-Chlorophenyl)-1-[5-[4-(2-methoxyphenyl)piperazin-1-yl]pentyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-91-0P**, 1-[3-(4-Chlorophenyl)-1-[6-[4-(2-methoxyphenyl)piperazin-1-yl]hexyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-92-1P**, 2-[1-[[5-Acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]methyl]-2-(4-o-tolylpiperazin-1-yl)ethoxy]acetamide **400803-93-2P**, [1-[[5-Acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]methyl]-2-(4-o-tolylpiperazin-1-yl)ethoxy]acetic acid **400803-94-3P**, [1-[[5-Acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]methyl]-2-(4-o-tolylpiperazin-1-yl)ethoxy]acetonitrile **400803-95-4P**, 1-[1-[3-[4-(2-Bromobenzenesulfonyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-97-6P**, 2-[4-[3-[3-(4-Chlorophenyl)-4,5,6,7-tetrahydroindazol-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400803-98-7P**, 2-[4-[3-[3-(4-Chlorophenyl)-4,5,6,7-tetrahydroindazol-1-yl]-2-hydroxypropyl]piperazin-1-yl]phenol **400803-99-8P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide **400804-00-4P**, 1-[1-[2-Azido-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-01-5P**, 1-[1-[2-Amino-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-02-6P**, 1-[3-(4-Chlorophenyl)-1-[2-methylamino-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-03-7P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400804-04-8P**, 3-(4-Chlorophenyl)-1-[2-

hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydroindazol-5-one ethylene ketal **400804-05-9P**, 1-[2-Hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400804-06-0P**, 1-[3-(4-Chloro-3-methylphenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-07-1P**, 2-[4-[3-[5-Acetyl-3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-08-2P**, 1-[1-[3-[4-(2-Chlorobenzenesulfonyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-09-3P**

, 1-[3-(4-Chloro-2-fluorophenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-10-6P**, 2-[4-[3-[5-Acetyl-3-(4-chloro-2-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-11-7P**, 1-[3-(4-Chlorophenyl)-5-methyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-(4-o-tolylpiperazin-1-yl)propan-2-ol **400804-12-8P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]-2-phenylethanone **400804-13-9P**, 1-[3-(4-Chlorophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-(4-o-tolylpiperazin-1-yl)propan-2-ol **400804-14-0P**, 1-[1-[3-[4-(2-Aminophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-15-1P**, N-[2-[4-[3-[5-Acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]phenyl]methanesulfonamide **400804-16-2P**, N-[2-[4-[3-[5-Acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]phenyl]acetamide **400804-17-3P**, 1-[2-[4-[3-[5-Acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]phenyl]-3-isopropylurea **400804-18-4P**

, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid hydrazide **400804-19-5P**, 2-[4-[3-[5-Acetyl-3-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-20-8P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid phenethylamide **400804-21-9P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid (4-methoxyphenyl)amide **400804-22-0P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carbothioic acid methylamide **400804-23-1P**, 2-[4-[3-[5-Acetyl-3-(4-chloro-3-nitrophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-24-2P**, 1-[2-Hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid ethylamide **400804-25-3P**, N-[5-[5-Acetyl-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl]methanesulfonamide **400804-26-4P**, 1-[3-(4-Chlorophenyl)-1-[2-[(1-ethylpyrrolidin-2-ylmethyl)amino]-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-27-5P**, 2-[4-[3-[5-Acetyl-3-(4-trifluoromethylsulfanylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-28-6P**, 2-[4-[3-[5-Acetyl-3-(3-amino-4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-29-7P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide **400804-30-0P**,

3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid phenylamide **400804-31-1P**, 1-[3-(4-Chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-(4-o-tolylpiperazin-1-yl)propan-2-ol **400804-32-2P**, 1-[3-(4-Iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-(4-o-tolylpiperazin-1-yl)propan-2-ol **400804-33-3P**, 2-[4-[3-[5-Acetyl-3-(4-methanesulfonylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-34-4P**, 1-[1-[2-Hydroxy-3-[4-(2-hydroxyphenyl)piperazin-1-yl]propyl]-3-(4-methanesulfonylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-35-5P**, 1-[3-(4-Iodophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-(4-o-tolylpiperazin-1-yl)propan-2-ol **400804-36-6P**, 1-[2-Hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide **400804-37-7P**, 1-[2-Hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester **400804-38-8P**, 1-[2-Hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid methylamide **400804-39-9P**, N-[5-[5-Acetyl-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl]methanesulfonamide **400804-40-2P**, 1-[5-[5-Acetyl-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl]-3-ethylurea **400804-41-3P**, 1-[5-[5-Acetyl-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl]-3-ethylurea **400804-42-4P**, N-[5-[5-Acetyl-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl]acetamide **400804-43-5P**, Acetic acid 2-[5-acetyl-3-(3-amino-4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-1-[[4-(2-cyanophenyl)piperazin-1-yl]methyl]ethyl ester **400804-44-6P**, N-[5-[5-Acetyl-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl]acetamide **400804-45-7P**, N-[2-[5-Acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-1-(4-o-tolylpiperazin-1-ylmethyl)ethyl]methanesulfonamide **400804-46-8P**, 1-[3-(4-Chlorophenyl)-1-[2-[[2-(pyridin-2-yl)ethyl]amino]-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-47-9P**, 1-[3-(4-Chlorophenyl)-1-[2-(2-dimethylaminoethylamino)-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-48-0P**, Carbonic acid 2-[5-acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-1-(4-o-tolylpiperazin-1-ylmethyl)ethyl methyl ester **400804-49-1P**, Carbamic acid 2-[5-acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-1-(4-o-tolylpiperazin-1-ylmethyl)ethyl ester **400804-50-4P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydroindazol-5-one **400804-51-5P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-indazol-5-ol **400804-52-6P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydroindazol-5-one oxime **400804-53-7P**, 1-[5-(Ethanesulfonyl)-3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-(4-o-tolylpiperazin-1-yl)propan-2-ol **400804-54-8P**, 1-[5-(4-Chlorobenzenesulfonyl)-3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-(4-o-tolylpiperazin-1-yl)propan-2-ol **400804-55-9P**, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid methylamide **400804-56-0P**, 1-[3-(4-Iodophenyl)-5-(propane-2-sulfonyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-(4-o-tolylpiperazin-1-yl)propan-2-ol

400804-57-1P, 1-[3-[4-(2-Cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carbonitrile **400804-60-6P**, 2-[4-[3-[5-Acetyl-3-(3-chloro-4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-61-7P**, 2-[4-[3-[5-Acetyl-3-(3-fluoro-4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-62-8P**, 2-[4-[3-[5-Acetyl-3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-ylmethyl]benzonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)

RN 400802-42-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-1-[3-[4-(2-fluorophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400802-44-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[2-methoxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-45-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-hydroxyphenyl)-1-piperazinyl]methyl]-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-49-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-N-[2-(1-piperazinyl)ethyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-51-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-52-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[2-[(aminocarbonyl)oxy]-3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)-(9CI) (CA INDEX NAME)



RN 400802-53-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-amino-4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-(9CI) (CA INDEX NAME)



RN 400802-54-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-bromophenyl)-.alpha.-[[4-(5-chloro-2-methylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400802-55-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-1-[3-[4-(2-cyanophenyl)-1-

piperazinyl]-2-fluoropropyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-56-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-acetic acid, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-.alpha.-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-57-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 4,5,6,7-tetrahydro-5-(methylsulfonyl)-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-58-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-[2-[(aminocarbonyl)amino]-6-chlorophenyl]-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-59-7 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-sulfonamide, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-60-0 CAPLUS
CN Methanesulfonamide, N-[3-chloro-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400802-61-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2,6-dinitrophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-62-2 CAPLUS
CN Benzoic acid, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-3-[(methylsulfonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-66-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-amino-6-chlorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-67-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-[6-chloro-2-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-68-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-[2-chloro-6-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-69-9 CAPLUS
CN Benzoic acid, 3-amino-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-71-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-bromophenyl)-.alpha.-[[4-[2-chloro-6-[[(methylamino)carbonyl]amino]phenyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-72-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-73-5 CAPLUS
CN Carbamic acid, [3-chloro-2-[4-[3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-75-7 CAPLUS
CN Benzoic acid, 2-[4-[3-[5-acetyl-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-1-piperazinyl]-3-nitro-, methyl ester (9CI) (CA INDEX NAME)



RN 400802-76-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-77-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-78-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-bromophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-79-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400802-80-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400802-81-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2,4-dimethylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400802-82-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(3,5-dichloro-4-pyridinyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-83-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400802-84-8 CAPLUS
CN Methanesulfonamide, N-[3-chloro-2-[4-[3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400802-85-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(3,4-dichlorophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400802-86-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400802-87-1 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-sulfonamide, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 400802-59-7
CMF C27 H33 Cl F3 N7 O4 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 400803-17-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 400803-18-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-3-(4-chlorophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-19-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-20-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-21-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(3-chlorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-22-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-23-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-24-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-25-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(3-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-26-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-27-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[(4-phenyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 400803-28-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(diphenylmethyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-29-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-31-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-33-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-3-(4-iodophenyl)-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-34-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-[2-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-35-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-37-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 400803-38-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(3,4-dichlorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-39-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-pyridinyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-40-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-[1,1'-biphenyl]-4-yl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-41-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 400803-42-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-3-(4-methoxyphenyl)-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-43-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-3-(4-methoxyphenyl)-.alpha.-[[4-(4-pyridinyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-45-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-46-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 400803-47-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-[4-(1,1-dimethylethyl)phenyl]-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-48-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-5-(1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 400803-49-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chlorophenyl)-5-(2,2-dimethyl-1-oxopropyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-50-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chlorophenyl)-4,5,6,7-tetrahydro-5-(4-methoxybenzoyl)-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-51-2 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400803-52-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-53-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3,4-dichlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-(9CI) (CA INDEX NAME)



RN 400803-54-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-3-[4-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 400803-55-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 400803-56-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-57-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-59-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(2,3-dimethylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-60-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(2,4-dimethylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-61-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(2,5-dimethylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-62-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[3-methyl-4-(4-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-63-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[3-methyl-4-(3-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-64-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-[4-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-65-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-66-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-(3,5-dichloro-4-pyridinyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-67-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-2-butenyl]- (9CI) (CA INDEX NAME)



RN 400803-68-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-cyanophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-71-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-[2,4-bis(trifluoromethyl)phenyl]-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-72-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(2,4-dichlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-73-8 CAPLUS
CN Benzonitrile, 2-[4-[3-[3-(4-chlorophenyl)-5,6-dihydro-1(4H)-cyclopentapyrazolyl]-2-hydroxypropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400803-74-9 CAPLUS
CN 1(4H)-Cyclopentapyrazoleethanol, 3-(4-chlorophenyl)-5,6-dihydro-.alpha.-[[4-(2-hydroxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-75-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-bromophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-76-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[3-[4-(2-methylphenyl)-1-piperazinyl]-2-[(2-methyl-2-propenyl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 400803-77-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[3-[4-(2-methylphenyl)-1-piperazinyl]-2-(phenylmethoxy)propyl]- (9CI) (CA INDEX NAME)



RN 400803-78-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 400803-79-4 CAPLUS
CN 4-Morpholinecarboxylic acid, 1-[[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



RN 400803-80-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-, benzoate (ester) (9CI) (CA INDEX NAME)



RN 400803-81-8 CAPLUS
CN Carbamic acid, benzoyl-, 1-[[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



RN 400803-83-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-hydroxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-84-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-chlorophenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-85-2 CAPLUS
CN Carbamic acid, (1,1-dimethylethyl)-, 1-[[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



RN 400803-86-3 CAPLUS
CN Carbonic acid, 1-[[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl methyl ester (9CI) (CA INDEX NAME)



RN 400803-87-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[4-[4-(2-hydroxyphenyl)-1-piperazinyl]-2-butenyl]- (9CI) (CA INDEX NAME)



RN 400803-88-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-1-[4-[4-(2-cyanophenyl)-1-piperazinyl]-2-butenyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-89-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400803-90-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[5-[4-(2-methoxyphenyl)-1-piperazinyl]pentyl]- (9CI) (CA INDEX NAME)



RN 400803-91-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1-[6-[4-(2-methoxyphenyl)-1-piperazinyl]hexyl]- (9CI) (CA INDEX NAME)



RN 400803-92-1 CAPLUS
CN Acetamide, 2-[1-[[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-2-[4-(2-methylphenyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 400803-93-2 CAPLUS
CN Acetic acid, [1-[[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-2-[4-(2-methylphenyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 400803-94-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-chlorophenyl)-1-[2-(cyanomethoxy)-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-95-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-[(2-bromophenyl)sulfonyl]-1-piperazinyl]methyl]-3-(4-chlorophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400803-97-6 CAPLUS
CN Benzonitrile, 2-[4-[3-[3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-hydroxypropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400803-98-7 CAPLUS
CN 1H-Indazole-1-ethanol, 3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-hydroxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-99-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 400804-00-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-1-[2-azido-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-3-(4-chlorophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-01-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-02-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-N-methyl-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-03-7 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400804-04-8 CAPLUS
CN Spiro[1,3-dioxolane-2,5'-[5H]indazole]-1'(4'H)-ethanol, 3'-(4-chlorophenyl)-6',7'-dihydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-05-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-3-(4-iodophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400804-06-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-07-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-08-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-.alpha.-[[4-[(2-chlorophenyl)sulfonyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-09-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-2-fluorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-(9CI) (CA INDEX NAME)



RN 400804-10-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-2-fluorophenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-(9CI) (CA INDEX NAME)



RN 400804-11-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chlorophenyl)-4,5,6,7-tetrahydro-5-methyl-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-(9CI) (CA INDEX NAME)



RN 400804-12-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-5-(phenylacetyl)- (9CI) (CA INDEX NAME)



RN 400804-13-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400804-14-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-aminophenyl)-1-piperazinyl]methyl]-3-(4-chlorophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-15-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-[2-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-16-2 CAPLUS
CN Acetamide, N-[2-[4-[3-[5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400804-17-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-[2-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-18-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-, hydrazide (9CI) (CA INDEX NAME)



RN 400804-19-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 400804-20-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 400804-21-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 400804-22-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carbothioamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 400804-23-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-nitrophenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-24-2 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-ethyl-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400804-25-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-[4-chloro-3-[(methylsulfonyl)amino]phenyl]-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-26-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-3-(4-chlorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-27-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 400804-28-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-amino-4-chlorophenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-29-7 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 400804-30-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 400804-31-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-32-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 4,5,6,7-tetrahydro-3-(4-iodophenyl)-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-33-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400804-34-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-hydroxyphenyl)-1-piperazinyl]methyl]-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400804-35-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 4,5,6,7-tetrahydro-3-(4-iodophenyl)-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400804-36-6 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400804-37-7 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-3-(4-iodophenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 400804-38-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-3-(4-iodophenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 400804-39-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-[4-chloro-3-[(methylsulfonyl)amino]phenyl]-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-40-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-[4-chloro-3-[[(ethylamino)carbonyl]amino]phenyl]-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-41-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-[4-chloro-3-[[(ethylamino)carbonyl]amino]phenyl]-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-42-4 CAPLUS
CN Acetamide, N-[5-[5-acetyl-4,5,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl]- (9CI) (CA INDEX NAME)



RN 400804-43-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-amino-4-chlorophenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-, acetate (ester) (9CI) (CA INDEX NAME)



RN 400804-44-6 CAPLUS
CN Acetamide, N-[5-[5-acetyl-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl]- (9CI) (CA INDEX NAME)



RN 400804-45-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 400804-46-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 400804-47-9 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanamine, 5-acetyl-3-(4-chlorophenyl)-N-[2-(dimethylamino)ethyl]-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-48-0 CAPLUS
CN Carbonic acid, 1-[[5-acetyl-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl methyl ester (9CI) (CA INDEX NAME)



RN 400804-49-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-3-[4-(trifluoromethyl)phenyl]-, carbamate (ester) (9CI) (CA INDEX NAME)



RN 400804-50-4 CAPLUS
CN 5H-Indazol-5-one, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400804-51-5 CAPLUS
CN 1H-Indazole-1-ethanol, 3-(4-chlorophenyl)-4,5,6,7-tetrahydro-5-hydroxy-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-52-6 CAPLUS
CN 5H-Indazol-5-one, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-, oxime (9CI) (CA INDEX NAME)



RN 400804-53-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-(ethylsulfonyl)-4,5,6,7-tetrahydro-3-(4-iodophenyl)-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-54-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-[(4-chlorophenyl)sulfonyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-55-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 400804-56-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 4,5,6,7-tetrahydro-3-(4-iodophenyl)-5-[(1-methylethyl)sulfonyl]-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-57-1 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carbonitrile, 1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400804-60-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-[3-chloro-4-(trifluoromethyl)phenyl]-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-61-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-3-[3-fluoro-4-(trifluoromethyl)phenyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-62-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-.alpha.-[[4-[(2-cyanophenyl)methyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



IT **400804-63-9P**, 1-[3-(4-Chloro-3-methylphenyl)-1-[2-hydroxy-3-[4-(2-methoxybenzyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-64-0P**, 2-[4-[3-[5-Acetyl-3-(4-bromo-3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-65-1P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxamidine **400804-66-2P**, 2-[4-[3-[5-Acetyl-3-(3,4-dichlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-67-3P**, 2-[4-[3-[5-Acetyl-3-(3,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-68-4P**, 2-[4-[3-[5-Acetyl-3-(3,5-dichlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-69-5P**, 2-[4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-(2-morpholin-4-ylethoxy)propyl]piperazin-1-yl]benzonitrile **400804-70-8P**, 2-[4-[2-Hydroxy-3-[3-(4-iodophenyl)-5-trifluoromethanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]benzonitrile **400804-71-9P**, 2-[4-[3-[5-Acetyl-3-(3-chloro-4-methylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-72-0P**, N-[4-[5-Acetyl-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl]acetamide **400804-73-1P**, 2-[4-[3-[5-Acetyl-3-(4-bromo-3-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-74-2P**, 1-[3-(3-Chloro-4-methylphenyl)-1-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-75-3P**, 1-[1-[3-[4-(2-Azidophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-

bromophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-76-4P**, 2-[4-[3-[5-Acetyl-3-(3-azido-4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400804-77-5P**, 5-Methanesulfonyl-1-[3-(4-o-tolylpiperazin-1-yl)propyl]-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400804-78-6P**, 5-Methanesulfonyl-1-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400804-79-7P**, 1-[1-[2-Hydroxy-3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-3-(4-nitrophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-80-0P**, 3-(4-Bromophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400804-81-1P**, 3-(4-Bromophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400804-82-2P**, 1-[3-(4-Bromophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-83-3P**, 3-(4-Bromophenyl)-5-methanesulfonyl-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400804-84-4P**, 3-(3,4-Dichlorophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400804-85-5P**, 3-(4-Bromophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-sulfonic acid amide **400804-86-6P**, 1-[3-(3,4-Dichlorophenyl)-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-87-7P**, 3-(3,4-Dichlorophenyl)-5-methanesulfonyl-1-[3-[4-(2-nitrophenyl)piperazin-1-yl]propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400804-93-5P**, 1-[4-(2,6-Dimethylphenyl)piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propan-2-ol **400804-94-6P**, 1-[1-[3-[4-(2,6-Dimethylphenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400804-95-7P**, 2-[4-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]isophthalonitrile **400804-96-8P**, 2-[4-[3-[5-Acetyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl)isophthalonitrile **400804-97-9P**, 3-Chloro-2-[4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]benzoic acid methyl ester **400804-98-0P**, 3-Chloro-2-[4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]-N-methylbenzamide **400804-99-1P**, [3-Chloro-2-[4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]phenyl]morpholin-4-ylmethanone **400805-00-7P** **400805-01-8P**, 3-Chloro-2-[4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]-N-pyridin-4-ylmethylbenzamide **400805-02-9P**, 2-[4-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]-3-nitrobenzoic acid methyl ester **400805-03-0P**, 3-Acetylamino-2-[4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]benzoic acid methyl ester **400805-04-1P**, 2-[4-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]-3-nitrobenzamide **400805-05-2P**, 2-[4-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]-3-(3-methylureido)benzoic acid methyl ester **400805-06-3P**, 1-[1-[3-[4-(2,6-

Dinitrophenyl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400805-07-4P 400805-08-5P**, 1-[1-[3-[4-(3,5-Dichloropyridin-4-yl)piperazin-1-yl]-2-hydroxypropyl]-3-(4-trifluoromethylsulfanylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400805-09-6P**, 1-[1-[3-[4-(3,5-Dichloropyridin-4-yl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400805-10-9P**, 2-[4-[3-[5-Acetyl-3-(4-bromophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-azido-propyl]piperazin-1-yl]benzonitrile **400824-64-8P**, 3-(4-Chlorophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)

RN 400804-63-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-[(2-methoxyphenyl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-64-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-bromo-3-methylphenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-65-1 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboximidamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400804-66-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-3-(3,4-dichlorophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-67-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-3-(3,4-difluorophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-68-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-3-(3,5-dichlorophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-69-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-[2-(4-morpholinyl)ethoxy]propyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400804-70-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)-5-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 400804-71-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-chloro-4-methylphenyl)-

.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-
(9CI) (CA INDEX NAME)



RN 400804-72-0 CAPLUS
CN Acetamide, N-[4-[5-acetyl-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-
hydroxypropyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl]-
(9CI) (CA INDEX NAME)



RN 400804-73-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-bromo-3-chlorophenyl)-
.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-
(9CI) (CA INDEX NAME)



RN 400804-74-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-chloro-4-methylphenyl)-
4,5,6,7-tetrahydro-.alpha.-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-
(9CI) (CA INDEX NAME)



RN 400804-75-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-azidophenyl)-1-piperazinyl]methyl]-3-(4-bromophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-76-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(3-azido-4-chlorophenyl)-.alpha.-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400804-77-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 4,5,6,7-tetrahydro-1-[3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400804-78-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 4,5,6,7-tetrahydro-1-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400804-79-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-4,5,6,7-tetrahydro-3-(4-nitrophenyl)-.alpha.-[[4-(2-nitrophenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400804-80-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(4-bromophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400804-81-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 3-(4-bromophenyl)-4,5,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400804-82-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-bromophenyl)-4,5,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400804-83-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 3-(4-bromophenyl)-4,5,6,7-tetrahydro-5-(methylsulfonyl)-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400804-84-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(3,4-dichlorophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400804-85-5 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-sulfonamide, 3-(4-bromophenyl)-1,4,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400804-86-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(3,4-dichlorophenyl)-4,5,6,7-tetrahydro-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400804-87-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 3-(3,4-dichlorophenyl)-4,5,6,7-tetrahydro-5-(methylsulfonyl)-1-[3-[4-(2-nitrophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 400804-93-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2,6-dimethylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400804-94-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2,6-dimethylphenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400804-95-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-(2,6-dicyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400804-96-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2,6-dicyanophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400804-97-9 CAPLUS
CN Benzoic acid, 3-chloro-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400804-98-0 CAPLUS
CN Benzamide, 3-chloro-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 400804-99-1 CAPLUS
CN Morpholine, 4-[3-chloro-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 400805-00-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, .alpha.-[[4-[2-chloro-6-(4-morpholinylmethyl)phenyl]-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400805-01-8 CAPLUS
CN Benzamide, 3-chloro-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 400805-02-9 CAPLUS
CN Benzoic acid, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-3-nitro-, methyl ester (9CI) (CA INDEX NAME)



RN 400805-03-0 CAPLUS
CN Benzoic acid, 3-(acetylamino)-2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400805-04-1 CAPLUS
CN Benzamide, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 400805-05-2 CAPLUS
CN Benzoic acid, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]-3-[[(methylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 400805-06-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2,6-dinitrophenyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400805-07-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(3,5-dichloro-4-pyridinyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400805-08-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(3,5-dichloro-4-pyridinyl)-1-piperazinyl]methyl]-4,5,6,7-tetrahydro-3-[4-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 400805-09-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-1-[3-[4-(3,5-dichloro-4-pyridinyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400805-10-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 5-acetyl-1-[2-azido-3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-3-(4-bromophenyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400824-64-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(4-chlorophenyl)-1,4,6,7-tetrahydro-1-[2-hydroxy-3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT **400802-96-2P**, 2-[4-[2-Hydroxy-3-[3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperazin-1-yl]benzonitrile **400802-99-5P**, 1-[3-(4-Chloro-3-nitrophenyl)-1-[2-hydroxy-3-(4-o-tolylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400803-03-4P**, 3-(4-Chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)piperazin-1-yl]-2-hydroxypropyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-04-5P**, 2-[4-[3-[3-(4-Chloro-3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperazin-1-yl]benzonitrile **400803-06-7P**, 1-[3-[4-(2-Chloro-6-nitrophenyl)piperazin-1-yl]propyl]-5-methanesulfonyl-3-(4-

trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine **400803-07-8P**, 1-[3-[4-(2-Chloro-6-nitrophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-08-9P**, 1-[3-[4-(2-Amino-6-chlorophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-09-0P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester **400803-10-3P**, 1-[3-[4-(2-Chloro-6-methanesulfonylaminophenyl)piperazin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-sulfonic acid (tert-butoxycarbonyl)amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of piperazinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)

RN 400802-96-2 CAPLUS
CN Benzonitrile, 2-[4-[2-hydroxy-3-[4,5,6,7-tetrahydro-3-(4-iodophenyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400802-99-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-nitrophenyl)-4,5,6,7-tetrahydro-.alpha.-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 400803-03-4 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(4-chloro-3-methylphenyl)-1-[3-[4-(2-cyanophenyl)-1-piperazinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-04-5 CAPLUS
CN Benzonitrile, 2-[4-[3-[3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 400803-06-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400803-07-8 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-chloro-6-nitrophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-08-9 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-(2-amino-6-chlorophenyl)-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-09-0 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 400803-10-3 CAPLUS
CN Carbamic acid, [[1-[3-[4-[2-chloro-6-[(methylsulfonyl)amino]phenyl]-1-piperazinyl]propyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]-5H-pyrazolo[4,3-c]pyridin-5-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:886128 CAPLUS
DOCUMENT NUMBER: 136:20084
TITLE: Preparation of 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as adenosine A2a receptor antagonists
INVENTOR(S): Neustadt, Bernard R.; Lindo, Neil A.; Greenlee, William J.; Tulshian, Deen; Silverman, Lisa S.; Xia, Yan; Boyle, Craig D.; Chackalamannil, Samuel
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001092264	A1	20011206	WO 2001-US16954	20010524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002099061	A1	20020725	US 2001-865071	20010524
US 6630475	B2	20031007		
EP 1283839	A1	20030219	EP 2001-945991	20010524
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003535094	T2	20031125	JP 2002-500877	20010524
NO 2002005651	A	20030123	NO 2002-5651	20021125

PRIORITY APPLN. INFO.: US 2000-207143P P 20000526
WO 2001-US16954 W 20010524
OTHER SOURCE(S): MARPAT 136:20084
GI



I

AB The title compds. [I; R = (un)substituted Ph, cycloalkenyl, heteroaryl; X = alkylene, COCH2; Y = O, S, CH2S, (CH2)2NH, etc.; Z = (un)substituted Ph, phenylalkyl heteroaryl, etc.; or Z and Y together are substituted piperidinyl or phenyl], useful in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, were prepd. and formulated. E.g., a multi-step synthesis of I [R = 2-furanyl; X = (CH2)2; ZY = 4-(2,4-difluorophenyl)piperazin-1-yl] was described. Compds. I showed Ki of 0.3-57 nM against A2a receptor binding.

IT **377728-74-0P 377728-75-1P 377728-76-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as adenosine A2a receptor antagonists)

RN 377728-74-0 CAPLUS
CN 7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[3-(4-phenyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 377728-75-1 CAPLUS
CN 7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 7-[3-[4-(4-chlorophenyl)-1-piperazinyl]propyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 377728-76-2 CAPLUS
CN 7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[3-[4-(4-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA

INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:575148 CAPLUS
DOCUMENT NUMBER: 134:36671
TITLE: Influence of the aliphatic spacer length on the 5-HT1A receptor activity of new arylpiperazines with an indazole system
AUTHOR(S): Paluchowska, Maria H.; Duszynska, Beata; Klodzinska, Aleksandra; Tatarczynska, Ewa
CORPORATE SOURCE: Department of Medicinal Chemistry, Polish Academy of Sciences, Krakow, PL 31-343, Pol.
SOURCE: Polish Journal of Pharmacology (2000), 52(3), 209-216
CODEN: PJPAE3; ISSN: 1230-6002
PUBLISHER: Polish Academy of Sciences, Institute of Pharmacology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Novel arylpiperazines, contg. a terminal 1- or 2-indazolyl fragment and a di- or tetramethylene aliph. spacer, were synthesized and their 5-HT1A and 5-HT2A receptor affinities were detd. All those compds. showed a potent affinity for 5-HT1A receptors (Ki = 5-16 nM) and were evaluated for an intrinsic activity at those receptors. To det. a 5-HT1A agonistic effect of the investigated compds., their ability to induce a lower lip retraction in rats and a behavioral syndrome (flat body posture and forepaw treading) in reserpinized rats were tested, whereas their 5-HT1A antagonistic activity was assessed via inhibition of those symptoms produced by 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT). The effect of spacer length on the 5-HT1A activity of the tested compds. was discussed in comparison with that of the 3-methylene analogs described earlier. Both dimethylene derivs. were characterized as weak postsynaptic 5-HT1A receptor antagonists. Compds. 1-indazolyl analog and 2-indazolyl analog, with a tetramethylene aliph. chain were classified as a postsynaptic 5-HT1A antagonist and a partial 5-HT1A agonist, resp. Furthermore, the latter showed a moderate anxiolytic-like effect (conflict drinking Vogel's test in rats) and a weak antidepressant-like activity (forced swimming Porsolt's test in rats).

IT **313053-44-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(arylpiperazines, new 5-HT1A receptor ligands)
RN 313053-44-0 CAPLUS
CN 1H-Indazole, 1-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:807683 CAPLUS
DOCUMENT NUMBER: 132:245821
TITLE: Structure-activity relationship studies of CNS agents. 40. Effect of the amide fragment on 5-HT1A receptor activity of some analogs of MP 3022
AUTHOR(S): Paluchowska, Maria H.; Charakchieva-Minol, Sijka; Tatarczynska, Ewa; Klodzinska, Aleksandra
CORPORATE SOURCE: Department of Medicinal Chemistry, Polish Academy of Sciences, Krakow, PL 31-343, Pol.
SOURCE: Polish Journal of Pharmacology (1999), 51(5), 415-421
CODEN: PJPAE3; ISSN: 1230-6002
PUBLISHER: Polish Academy of Sciences, Institute of Pharmacology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new set of analogs of MP 3022 (1) contg. the amide bond inserted into the intermediate chain linking the terminal heteroarom. and 1-(2-methoxyphenyl)piperazine moieties were prepd. and their 5-HT1A and 5-HT2A receptor affinities were detd. Only compds. with trimethylene chain between amide and arylpiperazine fragments showed satisfactory affinity for 5-HT1A receptor (Ki = 42-87 nM) and high 5-HT2A/5-HT1A selectivity. The new 5-HT1A receptor ligands were investigated in vivo to det. their 5-HT1A agonistic or antagonistic properties. Compds. with terminal indazole fragment or with Ph substituent behaved like weak 5-HT1A receptor antagonists. The structure-affinity relationship studies in this series of compds. revealed that the amide group along with the terminal arom. fragments contributed to interaction with 5-HT1A receptor sites, whereas in vivo results indicated that introduction of the amide group into presented arylpiperazine structures was not a profitable modification for their 5-HT1A functional activity.

IT **184535-35-1**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(5-HT1A receptor affinity of MP 3022 analogs)

RN 184535-35-1 CAPLUS
CN 1H-Indazole, 1-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:193935 CAPLUS
DOCUMENT NUMBER: 130:237561
TITLE: Indole and indazole derivatives, process for their preparation and the pharmaceutical compositions containing them
INVENTOR(S): Lavielle, Gilbert; Muller, Olivier; Vayssettes-Courchay, Christine; Descombes, Jean-Jacques; Verbeuren, Tony
PATENT ASSIGNEE(S): Adir et Compagnie, Fr.
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 902027	A1	19990317	EP 1998-402154	19980901
EP 902027	B1	20010725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2767827	A1	19990305	FR 1997-10939	19970903
BR 9803318	A	20000208	BR 1998-3318	19980901
AT 203531	E	20010815	AT 1998-402154	19980901
ES 2162404	T3	20011216	ES 1998-402154	19980901
NO 9804033	A	19990304	NO 1998-4033	19980902
CN 1218052	A	19990602	CN 1998-124581	19980902
CN 1087741	B	20020717		
NZ 331683	A	20000128	NZ 1998-331683	19980902
US 6020336	A	20000201	US 1998-146009	19980902
CA 2246485	AA	19990303	CA 1998-2246485	19980903
ZA 9808072	A	19990309	ZA 1998-8072	19980903
AU 9883068	A1	19990318	AU 1998-83068	19980903
AU 736602	B2	20010802		
JP 11130773	A2	19990518	JP 1998-249314	19980903
US 6046205	A	20000404	US 1999-299314	19990426
HK 1019738	A1	20021101	HK 1999-104871	19991028

PRIORITY APPLN. INFO.: FR 1997-10939 A 19970903
US 1998-146009 A3 19980902
OTHER SOURCE(S): MARPAT 130:237561
GI



I

AB The title compds. I [n = 0, 1; A = bond, alkylene, alkenylene; X = N, CR2 where R2 = H, alkyl; R1 = H, alkyl; G1 = pyrrolidinyl, piperidyl optionally substituted] were prepd. E.g., 1-{3-[4-(5-methoxypyrimidin-1-

yl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)indole dihydrochloride was prepd. Effect of I on contraction of saphenous vein of dogs or rabbits was detd.

IT **221249-30-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indole and indazole derivs. and their effect on saphenous vein contraction)

RN 221249-30-5 CAPLUS

CN 1H-Indazole, 1-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-6-(4H-1,2,4-triazol-4-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:148062 CAPLUS

DOCUMENT NUMBER: 130:276243

TITLE: Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1a serotonin and dopamine D1 receptors

AUTHOR(S): Andronati, S.; Sava, Vassil; Makan, S.; Kolodeev, G.

CORPORATE SOURCE: Bogatsky Physico-Chemical Institute, Nat. Acad. Sci. Ukraine, Odessa, 270086, Ukraine

SOURCE: Pharmazie (1999), 54(2), 99-101
CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Eight 3-arylindazole derivs. were synthesized and their affinity to 5-HT1A serotonin and D1 dopamine receptors was investigated by radioligand anal. Quant. structure-activity relationships were studied using the Free-Wilson model. An increase in affinity to dopamine D1 receptors within substituents Br>Cl>CH3 at the 5-position of the 3-arylindazole mol. was obsd. Addn. of a Cl2 atom to the ortho-position the of Ph ring let to even higher activity. Replacement of the H2 atom at the 1st position of the 3-arylindazole on the (phenylpiperazine)butyl substituent caused an increase of affinity and did not change the trends of affinity dependence on structure. An inverse dependence on the structure of the studied compds. was obsd. for the serotonin 5-HT1A receptors. Compds. contg. a Me group at the 5-position of mol. were more active than compds. contg. halogens. A Cl2 atom at the ortho-position of the Ph ring decreased affinity. Replacement of the H2 atom at the 1st position of the mol. on the (phenylpiperazine)butyl substituent led to an increase in affinity. Selectivity of the studied compds. varied within a wide range. Generally, the presence of the 3-arylindazole fragment in the new buspirone analogs increased their affinity to dopamine receptors and reduced their affinity to serotonin receptors. Compds. contg. a Br2 atom in the 3-arylindazole moiety may be promising ligands for D1 receptors.

IT **163434-05-7P 163434-06-8P 163434-07-9P**
163434-08-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of 3-arylindazole derivs. and their affinity to 5-HT1a serotonin and dopamine D1 receptors)

RN 163434-05-7 CAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163434-06-8 CAPLUS
CN 1H-Indazole, 5-bromo-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163434-07-9 CAPLUS
CN 1H-Indazole, 5-bromo-3-(2-chlorophenyl)-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163434-08-0 CAPLUS
CN 1H-Indazole, 5-methyl-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1996:701302 CAPLUS
DOCUMENT NUMBER: 126:47180
TITLE: Structure-activity relationship studies of CNS agents. Part 31. Analogs of MP 3022 with a different number of nitrogen atoms in the heteroaromatic fragment. New 5-HT1A receptor ligands
AUTHOR(S): Paluchowska, Maria H.; Deren-Wesolek, Anna; Mokrosz, Jerzy L.; Charakchieva-Minol, Sijka; Chojnacka-Wojcik, Ewa

09/288,556

CORPORATE SOURCE: Institute Pharmacology, Polish Academy Sciences, Krakow, 31-343, Pol.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 329(10), 451-456
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Two series of MP 3022 analogs , i.e. 1-(3-methoxyphenyl)-4-propylpiperazines and 2-propyl-1,2,3,4-tetrahydroisoquinolines contg. a terminal heteroarom. system with a different no. of N atoms, were synthesized and their 5-HT1A/5-HT2A and .alpha.1 receptor affinity was assayed. The majority of investigated piperazines is classified as non-selective 5-HT1A/5-HT2A/.alpha.1 receptor ligands. Six compds. with highest affinity for 5-HT1A receptors (Ki = 4-54 nM) were tested in vivo. Their functional activity was differentiated. While I (X, Y, Z = CH), I (X = N, Y, Z = CH), and I (X, Z = N, Y = CH) behaved like weak antagonists of postsynaptic 5-HT1A receptors, I (X, Z = CH, Y = N) and I (X = CH, Y = CMe, Z = N) are classified as potential partial 5-HT1A receptor agonists. Compd. II has characteristic features of a potential weak postsynaptic 5-HT1A receptor agonist.

IT **184535-35-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and 5-HT1A, 5HT2A, and .alpha.1-adrenergic receptor binding of MP 3022 analogs)

RN 184535-35-1 CAPLUS

CN 1H-Indazole, 1-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:490642 CAPLUS
DOCUMENT NUMBER: 122:314528
TITLE: Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]-1,2-dihydro-3H-1,4-benzodiazepin-2-ones and -1H-indazoles and their affinity for benzodiazepine receptors
AUTHOR(S): Andronati, S. A.; Kolodeyev, G. Ye.; Makan, S. Yu.; Sava, V. M.; Yavorsky, A. S.
CORPORATE SOURCE: Fiz.-Khim. Inst. im. A.V. Bogatskogo, Odessa, Ukraine
SOURCE: Dopovidi Akademii Nauk Ukraini (1994), (8), 126-31
CODEN: DNUKEM
PUBLISHER: Naukova Dumka
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



I



II



III

AB Title compds. I (R = H, Cl) and II (R1 = Cl, Br, Me, R2 = H; R1 = Br, R2 = Cl) were prepd. by reaction of spiro compd. III with 1-unsubstituted benzodiazepinones and indazoles. The effect of the (phenylpiperazinyl)butyl group on the affinity to benzodiazepine receptors was examd.

IT **163434-05-7P 163434-06-8P 163434-07-9P 163434-08-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(effect of (phenylpiperazinyl)butyl group on benzodiazepine receptor affinity of benzodiazepinones and indazoles)

RN 163434-05-7 CAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-,

monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163434-06-8 CAPLUS
CN 1H-Indazole, 5-bromo-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163434-07-9 CAPLUS
CN 1H-Indazole, 5-bromo-3-(2-chlorophenyl)-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163434-08-0 CAPLUS
CN 1H-Indazole, 5-methyl-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1977:453281 CAPLUS
DOCUMENT NUMBER: 87:53281
TITLE: Indazole derivatives
INVENTOR(S): Fujimura, Yasuo; Nagano, Hiroyuki; Shindo, Minoru; Kakimoto, Morio; Iwasaki, Tsuneo; Ikeda, Yugo
PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

09/288,556

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52014765	A2	19770203	JP 1975-90172	19750725
JP 59036627	B4	19840905		

PRIORITY APPLN. INFO.: JP 1975-90172 19750725

GI



I, R=NR2R3

II, R=X

AB Twenty indazole derivs. I (R1 = H, Me, Cl, Br; R2, R3 = H, Me, Et, H2C:CHCH2, PhCH2; R2R3N may form a morpholino, piperidino, or 4-substituted piperazino group; n = 2, 3) were prepd. by reaction of II (X = halo) with R2R3NH. I had central nervous system depressant, antidepressant, and antiinflammatory activities (no data). Thus, refluxing 3.4 g II (R1 = Cl, X = Br, n = 2) (prepd. by reaction of 3-phenyl-5-chloroindazole with 1,2-dibromoethane in DMF contg. NaH) with 1.83 g morpholine 10 h gave 2.8 g I (R1 = Cl, R2R3N = morpholino, n = 2), which was converted into its hydrochloride.

IT **63380-46-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 63380-46-1 CAPLUS

CN 1H-Indazole, 5-methyl-3-phenyl-1-[3-(4-phenyl-1-piperazinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1976:31053 CAPLUS

DOCUMENT NUMBER: 84:31053

TITLE: Indazole derivatives

INVENTOR(S): Fujimura, Yasuo; Nagano, Hiroyuki; Shindo, Minoru;

Kakimoto, Morio; Iwasaki, Tsuneo; Ikeda, Yugo
PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan
SOURCE: Ger. Offen., 27 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2503815	A1	19750807	DE 1975-2503815	19750130
DE 2503815	C2	19860522		
JP 50106958	A2	19750822	JP 1974-12184	19740131
JP 56037984	B4	19810903		
JP 50148355	A2	19751127	JP 1974-55000	19740518
JP 59022708	B4	19840528		
JP 50154244	A2	19751212	JP 1974-61853	19740603
JP 56052904	B4	19811215		
JP 51056446	A2	19760518	JP 1974-129521	19741112
JP 60003063	B4	19850125		
JP 51063172	A2	19760601	JP 1974-135184	19741126
JP 59044313	B4	19841029		
GB 1489280	A	19771019	GB 1975-2247	19750117
FR 2259601	A1	19750829	FR 1975-2955	19750130
FR 2259601	B1	19800111		

PRIORITY APPLN. INFO.:
JP 1974-12184 19740131
JP 1974-55000 19740518
JP 1974-61853 19740603
JP 1974-129521 19741112
JP 1974-135184 19741126

GI For diagram(s), see printed CA Issue.

AB Indazoles I (R = R1 = H, Me, Et; R = H, R1 = Me, Bu, allyl; NRR1 = piperidino, morpholino, N-methylpiperazino, N-phenylpiperazino, 2-(4-chlorophenyl-4-methyl-1,2,3,6-tetrahydropyridino, pyrrolidino; R2 = H, Cl, Me, Br, F; n = 1-3) were prepd. by treating indazoles with Cl(CH2)nNRR1, by Mannich reaction of indazoles, or by redn. of carbamoylalkylindazoles. Thus, 3-phenylindazole was treated with Me2NCH2CH2Cl.HCl to give I (R = R1 = Me, R2 = H, n = 2), which at 100 mg/kg orally in mice had a barbiturate potentiation value of 3.0, compared with imipramine 1.3. I were also antidepressant.

IT **57614-55-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 57614-55-8 CAPLUS

CN 1H-Indazole, 5-methyl-3-phenyl-1-[3-(4-phenyl-1-piperazinyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)